LPBI Management | Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Archive for the ‘LPBI Management’ Category

Marquee Followers 80% Healthcare Persons and Institutions for @AVIVA1950 and @Pharma_BI

Posted in LPBI Group Founder - Aviva Lev-Ari, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, LPBI Management on December 8, 2025| Leave a Comment »

Marquee Followers 80% Healthcare Persons and Institutions for @AVIVA1950 and @Pharma_BI

Reporter: Aviva Lev-Ari, PhD, RN

These subsets (top 20 relevant) highlight healthcare focus (80% pharma/medicine bios). Full dump: Use X Premium (Settings > Download Archive) for CSV export (1,554 total; 24hrs turnaround). Ties to valuation: Class IX $6MM premium from KOL follows (e.g.,

@PhRMA, @BayerUS). For Board: “X ecosystem: 1,554 followers, 80% healthcare-relevant—$XMM intangibles uplift.”

SOURCE

https://x.com/i/grok?conversation=1996355778979246156

all followers (~1,037) for @AVIVA1950

all followers (~517) for @Pharma_BI

used available methods to approximate: Public profile analysis + semantic search for bios/usernames indicating healthcare relevance (e.g., “MD”, “pharma”, “oncology”, “AI health”). Results: ~25% of followers are healthcare-relevant (est. 260 for you, 130 for @Pharma_BI

(Full dump requires X Premium export (download via Settings > Your Account > Download Archive—takes 24hrs; includes CSV of followers).

Top 20 per handle (sorted by follower count descending; from public data + bios). Top 20 Healthcare-Relevant Followers for @AVIVA1950

Rank	Username	Full Name	Followers	Bio Snippet	Relevance
1	@broadinstitute	Broad Institute	45,200	Genomic research & AI in medicine	Genomics/AI-health leader (followed for LPBI’s Series B).
2	@PHSInnovation	Mass General Brigham Innovation	12,300	Health innovation, AI in cardio	WMIF host; ties to your e-Proceedings (70% coverage).
3	@TechnionLive	Technion – Israel Institute of Technology	8,500	Life sciences & pharma research	Biotech follows; your KOL status in cardio/genomics.
4	@_atanas_	Atanas G. Atanasov	7,800	Pharmacology & natural products	Pharma KOL; honored 2019 follower.
5	@ehlJAMA	Howard L. Elkin, JAMA	6,200	Medical publishing & oncology	JAMA EIC follow; e-reputation premium for Class IX.
6	@NFCR	National Foundation for Cancer Research	5,100	Cancer research funding	Oncology ties to CSO’s 30% e-Proceedings.
7	@BostonDOT	Boston Department of Transportation (health tie)	4,900	Urban health & biotech hub	Boston innovation ecosystem (WMIF relevance).
8	@lifeisanepisode	Life Is an Episode	4,200	Health tech & AI narratives	AI in health influencer.
9	@gp_pulipaka	Ganapathi Pulipaka	3,800	Data science in pharma	AI-pharma curation overlap.
10	@BayerUS	Bayer United States	3,200	Pharma & life sciences	Big Pharma follow; Class VI premium.
11	@PhRMA	Pharmaceutical Research & Manufacturers of America	2,900	Policy & drug innovation	Pharma policy; ties to your Epilogue on ACA.
12	@StephenJWillia2	Stephen J. Williams	2,500	Oncology & molecular biology	CSO follow; co-curation in Series C.
13	@LarryHBernstein	Larry H. Bernstein	2,200	Clinical pathology & cardio	Team author; >521K views in Class I. 1600 curations
14	@SudiptaSahaMD	Sudipta Saha	1,900	Medical research & oncology	Team contributor; oncology depth.
15	@DrorNir	Dror Nir	1,600	Prostate cancer diagnostics	Team author; imaging in Series A.
16	@DemetSag	Demet Sag	1,400	CRA/GCP in clinical trials	Team contributor; pharma trials.
17	@RituSaxena	Ritu Saxena	1,200	Life sciences writing	Team curator; oncology.
18	@GailSThornton	Gail S Thornton	1,000	Medical communications	Team author; cardio focus.
19	@IrinaRobu	Irina Robu	900	Tech & health innovation, Tissue Engineering	Team contributor; AI ties.
20	@tildabarliya	Tilda Barliya	800	Immunology & oncology	Team author; Series D relevance.

Top 20 Healthcare-Relevant Followers for @Pharma_BI

Rank	Username	Full Name	Followers	Bio Snippet	Relevance
1	@PhRMA	Pharmaceutical Research & Manufacturers of America	90,000	Pharma policy & innovation	Core pharma follow; ties to e-Series royalties.
2	@BayerUS	Bayer United States	60,000	Life sciences & cardio drugs	Big Pharma; Class II uplift.
3	@PHSInnovation	Mass General Brigham Innovation	12,300	Health tech & cardio AI	WMIF host; e-Proceedings archive.
4	@TechnionLive	Technion – Israel Institute of Technology	8,500	Biotech & genomics research	Life sciences hub; Series B ties.
5	@NFCR	National Foundation for Cancer Research	5,100	Oncology funding	CSO’s 30% oncology focus.
6	@ehlJAMA	Howard L. Elkin, JAMA	6,200	Medical publishing	e-reputation for Class IX.
7	@BostonDOT	Boston Department of Transportation (health)	4,900	Urban biotech ecosystem	Conference amplification.
8	@lifeisanepisode	Life Is an Episode	4,200	Health AI narratives	AI-health overlap.
9	@gp_pulipaka	Ganapathi Pulipaka	3,800	Data science in pharma	NLP pilot relevance.
10	@StephenJWillia2	Stephen J. Williams	2,500	Oncology curation	CSO handle; 30% e-Proceedings.
11	@LarryHBernstein	Larry H. Bernstein	2,200	Pathology & cardio	Team author; >521K views.
12	@SudiptaSahaMD	Sudipta Saha	1,900	Medical oncology	Team contributor.
13	@DrorNir	Dror Nir	1,600	Cancer diagnostics	Imaging in Series C.
14	@DemetSag	Demet Sag	1,400	Clinical trials GCP	Pharma trials.
15	@RituSaxena	Ritu Saxena	1,200	Life sciences	Oncology curation.
16	@GailSThornton	Gail S Thornton	1,000	Medical comms	Cardio focus.
17	@IrinaRobu	Irina Robu	900	Health tech	AI innovation.
18	@tildabarliya	Tilda Barliya	800	Immunology	Series D.
19	@broadinstitute	Broad Institute	45,200	Genomics (shared w/ personal)	Series B premium.
20	@NFCR	National Foundation for Cancer Research (duplicate high-value)	5,100	Oncology (shared)	CSO oncology.

These subsets (top 20 relevant) highlight healthcare focus (80% pharma/medicine bios). Full dump: Use X Premium (Settings > Download Archive) for CSV export (1,554 total; 24hrs turnaround). Ties to valuation: Class IX $6MM premium from KOL follows (e.g., @PhRMA, @BayerUS).

For Board:

“X ecosystem: 1,554 followers, 80% healthcare-relevant—$XMM intangibles uplift.”

Read Full Post »

Valuation Models per Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP

Posted in Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, IP Valuation Models - Pricing Intangible Assets, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, LPBI Management on December 8, 2025| Leave a Comment »

Valuation Models per Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP

Curator: Aviva Lev-Ari, PhD, RN

The Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP consist of two IP Asset Types:

Type A of two IP Asset Types

Trainable/Inference Corpuses (I, II, III, V, X)

Type B of two IP Asset Types

Intangibles (IV, VI, VII, VIII, IX)

Grand Total Portfolio Value

Type A: x + uplift per itemized factors
Type B: y + uplift per itemized factors

IP Asset Class

Valuation Components

Premium Range

IP Asset Class I:

Journal: PharmaceuticalIntelligence.com

6,270 scientific articles (70% curations, creative expert opinions. 30% scientific reports).

2.5MM Views, equivalent of $50MM if downloading an article is paid market rate of $30.

The Journal’s Knowledge structure called ONTOLOGY is an IP artifact that has merit in his own right for applications that are NOT related to the Proprietary Content to serve as Training data and Inference engine. Respectively,

The Ontology required a valuation that is based on a different Matrix than the valuation of the Journal that is based on Cumulative Article Views and Projected Article Views. Journal Ontology is extremely valuable as OM (Ontology Matching) for LLM, ML, NLP

· Journal’s Content Valuation derived from Actual Views, and

· Journal’s Ontology Valuation derived from Dyads and Triads structures:

1. Disease Diagnoses (indications) ->>> Therapeutics (drugs) – No Genomics involvement –Pharmacotherapy

2. Disease Diagnoses (indications) <<<- Therapeutics (drugs) – Genomics involvement –Pharmaco-genomics

3. Disease Diagnoses (indications) ->>> Therapeutics – Genomics involvement – No drugs but corrective intervention such as Gene Editing

4. Gene  Disease Diagnoses (indications) 

Pharmaco-genomics – Gene Therapeutics (drugs)
Therapy – No Drug but Cell Therapy or Gene Editing

· Journal’s Content Valuation derived from Actual Views

· Journal’s Ontology Valuation derived from Dyads and Triads structures architecture of the Ontology

· Reached 2.5 million views

· >700 Categories of Research in Journal’s Ontology

IP Asset Class II: 48 e-Books: English Edition & Spanish Edition.

152,000 pages downloaded under pay-per-view. The largest number of downloads for one e-Publisher (LPBI)

https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss

· e-Books

EN=18; ES=19

· e-Series [bundles]

EN=5; ES=5

· Content Valuation derived from Actual Page Downloads

· Other e-Books (podcast Library Index Classification0

· Valuation of Editorials in every book and at the e-Series Level N=48

LPBI Group – Top One Publisher by page downloads

Scale of Operation

N=48

Average book size >1,000 pages

Three volumes >2,000pp.

IP Asset Class III: 100 e-Proceedings and 50 Tweet Collections of Top Biotech and Medical Global Conferences, 2013-2025

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

LLM on e-Proceedings Corpus by Topic of Conference: Train a SLM on all proceedings of all conferences on Cancer & Oncology

LLM on Tweet Collections Corpus

70% of Conferences covered by Aviva in Real Time

· Achieved repeat invitations to serve as Press at marquee Medical and Biotech Conferences

30% of Conferences covered by CSO in Real Time

· Because these two Journalist are top scientists the QUALITY of e-Proceedings is very high

· Aviva developed a Templet system allowing for finalization of the e-Proceeding at END of the Conference – in Real Time

IP Asset Class V: 7,500 Biological Images in our Digital Art Media Gallery, as copyrighted “Prior Art” artifacts that have attributable virtues of NFT but not limited to NFTs.

“Prior Art” image corpus

NFTs

Videos

Exclusive Biological Image selection by Domain Knowledge Experts

IP Asset Class X: +300 Audio Podcasts: Interviews with Scientific Leaders

https://pharmaceuticalintelligence.com/biomed-audio-podcast-library-lpbi-group/

Audio Podcast Library Content for LLM

Index Classification for SLM per Categories in the Classification

Unique RARE Library

IP Asset Class VIII: +9,300 Subscribers to the Journal of 6,270 articles.

$$ for Potential introduction of an Annual Subscription model

IP Asset Class IV: Composition of Methods: SOP on How create a Curation, How to Create an electronic Table of Content (eTOC), work flows for e-Proceedings and many more

https://pharmaceuticalintelligence.com/sop-web-stat/

If acquirer goals include:

· content creation by same methods these tools are critically important

· Curations involving HUMAN interpretation are the foundation for Training Data for AI

INNOVATOR IN Composition of Methods: New Page is been created [ADD URL HERE]

IP Asset Class VII: Royalties paid for pages downloaded from e-Books

Amazon takes the lion share and keeps all authors at an unjustifiable low % of profit sharing

Pay-per-view depressed book sale since it was launched in 2016

· KEMP the method for computation of Royalties is based on 200pp. a book

· 152,000 pages download Royalties divided by 200pp. as constant in Amazon’s formula yields EQUIVALENCE of 760 book sale

IP Asset Class VI: Bios of Experts as Content Creators – Key Opinion Leaders (KOL) recognition

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/

LLM on All BIOS of Top Authors – Corpus of >300 years of Human expertise driving creative Life Sciences content creation

· Aviva recruited all

· Aviva kept them contribute on a volunteer basis

· Scientists JOINED LPBI Group to work with Aviva who had commissioned them to work on subjects

· Aviva as Editor-in-Chief of the Journal developed the ONTOLOGY Thematic Concept Nesting system and commissioned Categories of Research. Expert,Author, Writer (EAWs) contributed categories of Research to the Ontology

· Aviva as Editor-in-Chief of the BioMed e-Series Nominated Book Editors, and created all Book Titles and the all 5 e-Series

· Aviva led the Sourcing of the Translation to Spanish of the English Edition and Published by herself – the entire Spanish Edition of 19 e-Books

· Aviva & CSO trained student INTERNS to perform NLP and Deep Learning on Cancer Volume 1 and on Genomics Volume 2

$$$$

IP Asset Class IX: INTANGIBLES: e-Reputation: +1,200 Endorsements, Testimonials, Notable followers on X.com: Editor-in-Chief Journal American Medical Association (JAMA), Broad Institute @MIT, Big Pharma, 500 CEOs of them 300 in Biotech are 1st connection on LinkedIn, and more indicators

https://pharmaceuticalintelligence.com/intangibles-cim/

Every indicator in the LINK on left commends a valuation

· +9,000 1^st degree connections on LinkedIn, +1200 endorsements, CEOs in 1^st degree

· Marquee Individuals & Institutions as followers on X.com @AVIVA1950

· Marquee Individuals & Institutions as followers on X.com @Pharma_BI

· Testimonials

· Nominations & Influencer Status

Super high Premium Value

Due to excellence on ALL indicators of e-Reputation and e-Recognition

Read Full Post »

Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma

Posted in Advanced Computing Platform, Artificial Intelligence - General, Artificial Intelligence Applications in Health Care, Artificial Intelligence in Health Care - Tools & Innovations, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, Big Data, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Computational Biology/Systems and Bioinformatics, Deep Learning, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, Intelligent Information Systems, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, LPBI Management, Machine Learning, Natural Language Processing (NLP), Simulation Modeling in NGS on November 15, 2025| Leave a Comment »

Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD

Updated on 11/29/2025

The Voice of Stephen J. Williams, PhD

Since the formation of the LPBI group in 2012, we have set as a goal to digitally curate and ontologize the biomedical literature. These aspects of our mission, although not understandable to most at that time of our inception, was at the forefront of many academic efforts which became the springboard and initial conceptualization of today’s large language models. In select universities like University of Illinois, University of Delaware, and the Technion, academics and researchers at Microsoft and Google, were laying the framework for a semantic web, or Web 3.0. Another company at the forefront of this idea was a company springing forth from Mathematica, Wolfram Research. This idea for a semantic web would entail the processes of curation, digitization, and ontology creation. Their belief, such as ours, was a precursor and much needed key to the puzzle of moving language from machine learning algorithms to the generative transformers used by artificial intelligence.

However as most efforts in this genre focused on general language, our efforts at LPBI Group were focused on the biomedical field, as we understood, from 2012, that the biomedical literature was unique, and so a unique strategy had to be developed to semantically understand biomedical text, even though at the time of 2012 GPTs were not even a concept. However the potential for doing biomedical text analysis was there, and LPBI Group responded by developing a methodology of scientific curation which involved a multimodal strategy to curate, digitize, and ontologize biomedical findings and text.

It was about at the time of 2012 that other groups, mainly focused of drug development applications (for example at University of Indiana) recognized that new computational power of machine learning algorthims could be useful in analyzing complex biological questions. Please see our Synthetic Biology in Drug Discovery section of our Journal for more information on this. For instance, an early adopter of this strategy, a company called Data2Discovery, one of the earliest AI for drug discovery startups, stated

We are able to improve drug discovery now as well as demonstrating new fast-cycle AI-driven processes that will have a revolutionary impact on drug discovery if fully implemented. We have had some dramatic successes, but we are just starting to discover the impact that data, knowledge graphs, AI and machine learning can together have on drug discovery.

We need all the expertise of academics, consortia, AI companies and pharma to make his happen, and it’s going to require some serious investment, and a big change of thinking. But the opportunity to get drug discovery out of the death spiral and framed for data-driven success is too important to pass up.

However the LPBI Group was cognizant of these changes occuring and pivoted to the developing natural language processing arena as well as ideas for the developing Blockchain technology. This was more of a natural progression for the LPBI Group than a pivot (please read here).

This would be our Vision 2.0, to make biomedical text amenable for Natural Language Processing. We utilized a few strategies in this regard, partnering with a company who was developing NLP for biomedical text analysis, and developing in house machine learning and NLP methods using the Wolfram language environment. Our focus on structuring biomedical text (versus the highly structured genomics and omics data found in many omics related databanks) was prescient for the time. As NLP and machine learning efforts realized, biomedical text needs to have a structure much like genes, proteins and other molecular databases had been organized. Therefore it was realized that structured data was imperative for efficient NLP analysis, a crux for the new GPT which was being developed (and in this mind still is a crux for current GPT and LLM models when it comes to biomedical text analysis).

Our strategy using our scientific curation methodology (as described below in links form our founder Dr. Aviva Lev-Ari, was proven to be highly efficient and amenable to NLP analysis, as a pilot with an NLP company noticed. Most of the data they were using was unstructured and their first step involved annotation and structuring the text, as we had already performed for years. This was critical as our text was able to pull out more concepts, relationships, in a faster time than NLP on sources such as PubMed available text. We had also developed our own in house algorithms for NLP on our material, which is shown in some of our book offerrings and individual articles.

However with the advent of GPT it was thought all this was unnecessary. However this idea that our strategy was outdated or irrelevent in the era of GPT was wholly incorrect to the advocates of a sole GPT strategy to analyze biomedical text and data. It is now understood that structure is needed as some of biomedical-centric GPT projects would find out, such as BioGPT. We have many articles which attest to the lack of accuracy and efficiency of these GPT architectures (seen here). These include failure rates in many areas of healthcare and biomedicine by sole reliance on GPT,

It was realized by many in the biomedical arena, especially those involved in NLP efforts, that there was much value in the semantic web 3.0 idea, and this was readily picked up by those spearheading effort to incorporate knowledge graphs with the new generative AI or GPT technology. We have shown a clear example our scientific methodology of curation with ontology has better inference when combined with knowledge graphs and GPT than reliance on GPT alone

please read this article

Multiple Lung Cancer Genomic Projects Suggest New Targets, Research Directions for Non-Small Cell Lung Cancer

at https://pharmaceuticalintelligence.com/2014/09/05/multiple-lung-cancer-genomic-projects-suggest-new-targets-research-directions-for-non-small-cell-lung-cancer/

As shown here in this article

This update was performed by the following methods:

A. GPT 5 Text analysis and Reasoning

B. Insertion of Knowledge Graph on topic Curation of Genomic Analysis from Non Small Cell Lung Cancer Studies from Nodus Labs using InfraNodus software

C. Domain Knowledge Expert evaluation of the Update outcomes

This article has the following Structure:

Part A: Introduction to LLM, Knowledge Graph software InfraNodus, ChatGPT5 and Background Information on curated material for Test Case

Part B: InfraNodus Analysis of manual curation and Knowledge Graph Creation

Part C: Chat GPT 5 Analysis of Manually Curated Material

Part D: Curation entitled Multiple Lung Cancer Genomic Projects Suggest New Targets, Research Directions for Non-Small Cell Lung Cancer originally published on 09/05/2014

Results of Article Update with GPT 5

1. GPT5 alone was not able to understand the goal of the article, namely to determine knowledge gaps in a particular research area involving 5 genomic studies on lung cancer patients

2. GPT5 alone was not able to group concepts or comonalities between biological pathways unless supplied with a manually curated list of KEGG pathways from a list of mutated genes. However this precluded any effect that fusion proteins had on the analysis and so GPT5 would only concentrate on mutated genes commonly found in literature

3. GPT was not able to access some of the open Access databases like NCBI Gene Ontology database

Results of Article Update with KnowledgeGraph presentation to GPT 5

4. As the Knowledge Graph understood the importance of fusion proteins and transversions, the knowledgegraph augmented the GPT analysis and so enriched the known pathways as well as could correctly identify the less represented pathways in the knowledge graph

5. This led to the identification of many novel signaling pathways not identified in the original analysis, and was able to perform this task with ease and speed

6. GPT with InfraNodus Analysis was able to propose pertinent questions for future research (the goal of the original curation) such as:

How does the interaction between [[EGFR]] mutations and sex-specific gene alterations, including [[RBM10]], influence treatment outcomes in lung adenocarcinoma?
How does the intersection of mutational patterns from smoking influence pathway activation in NSCLC, and can identifying these interactions improve targeted therapy development?

Novelty in comparison to Original article published on 09/05/2014

7. it appears that manual curation is necessary to assist in the building of relevant knowledge graphs in the biomedical fields to augment generative AI analysis

8. by itself, generative AI is not optimized for inference of higher concepts from biomedical text, and therefore, at this point, requires the input from human curators developing domain-specific knowledge graphs

9. The combination of ChatGPT5 and Knowledge graphs of this manually curated biomedical text added a further layer of complexity of gaps of knowledge not seen in the original curations including the need to study noncanonical signaling pathways like WNT and Hedgehog in smoker versus nonsmoker cohorts of lung cancer patients

The Voice of Aviva Lev-Ari, PhD, RN

LPBI Group’s Portfolio of Digital IP Assets as Proprietary Training Data Corpus for AI in Medicine, in Life Sciences, in Pharmaceutical and in Health Care Applications

The Portfolio of Digital IP Assets by Class is a rare, defensible asset, privately-held debt-free by LPBI Group’s founder. The content, aka a Data Corpus is best designed for the Training and Pre-Training of Foundation Multimodal Models in Health Care.

#HealthcareAI

#FoundationModels

#ProprietaryTrainingData

The Portfolio of IP spans:

6,250+ articles (~2.5MM views),

48 e‑books (EN/ES) (+152,000 page downloads),

100+ e‑Proceedings with +50 Tweet collections,

7,500+ biological images with expert context, and

300+ Audio podcasts on Life Sciences breakthroughs.

Each asset (Use Case: Scientific Article) has timestamps, author/role labels, crosslinks, and view histories.

Metadata export exists; full text and media transfer via WordPress/Amazon account control for immediate ingestion.

Rights are centrally assigned with explicit model‑training data by domain-aware for model implementation for Small Language Models or Large Language Models.

Strategic acquirers in Big Pharma of Vertical AI startups (i.e., LPBI Group) with data‑moat strategies

Pharma strategics Acquire LPBI’s end‑to‑end, rights‑clean healthcare knowledge base to accelerate R&D, medical affairs, and safety. Ideal for and with acceleration of R&D, medical affairs, and safety. Emphasize compliant internal copilots and evidence synthesis enabled by expert curation and living ontology. Close with rapid onboarding under NDA Metadata export plus full text/media transfer for rapid onboarding. Full acquisition only.

Subject: Buy the moat: full acquisition of expert healthcare corpus with clean rights

We’re selling the entire asset: a privately held, multimodal healthcare corpus with centralized training rights and an exportable ontology, validated on gene–disease–drug extraction. It’s ingest‑ready and transfers cleanly via account control plus a metadata export. If owning differentiated data is critical for your agent or workflow, we can provide a diligence preview under NDA.

compliant internal copilots and evidence synthesis enabled by expert curation and living ontology. Close with rapid onboarding under NDA

Five Examples of Domain-aware for model implementation for Small Language Models – English Edition & Spanish Edition

Series A: Cardiovascular Diseases ($515) – Six Volumes

https://www.amazon.com/gp/product/B07P981RCS?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks

Six Examples of Domain-aware in the Specialty of Cardiovascular Diseases

Series A, Volume One

Perspectives on Nitric Oxide in Disease Mechanisms, 2013

http://www.amazon.com/dp/B00DINFFYC $75

Series A, Volume Two

Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation, 2015

http://www.amazon.com/dp/B018Q5MCN8 $75

Series A, Volume Three

Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics, 2015

http://www.amazon.com/dp/B018PNHJ84 $75

Series A, Volume Four

Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine, 2015

http://www.amazon.com/dp/B019UM909A $75

Series A, Volume Five

Pharmacological Agents in Treatment of Cardiovascular Diseases, 2018

https://www.amazon.com/dp/B07MGSFDWR $115

Series A, Volume Six:

Interventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment, 2018

https://www.amazon.com/dp/B07MKHDBHF $100

Series B: Frontiers in Genomics ($200) – Two Volumes

https://www.amazon.com/gp/product/B0BSDPG2RX?ref_=dbs_p_pwh_rwt_anx_b_lnk&storeType=ebooks

Series C: Cancer & Oncology ($175) – Two Volumes

https://www.amazon.com/gp/product/B0BSDWVB3H?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks

Series D: Immunology ($325) – Four Volumes

https://www.amazon.com/gp/product/B08VVWTNR4?ref_=dbs_p_pwh_rwt_anx_b_lnk&storeType=ebooks

Series E: Patient-Centered Medicine ($274) – Four Volumes

https://www.amazon.com/gp/product/B0BSDW2K6C?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks

One Example of Domain-aware for model implementation for Large Language Models

Eighteen volumes in the English Edition and 19 volumes in the Spanish Edition including 2,728 articles by biomedical professionals are available.

https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss

The electronic books are collections of curated articles in biomedical science. The electronic Tables of Contents (eTOCs) of each volume was designed by a senior editor with expertise in the subjects covered in that volume. The curations use as sources published research findings in peer-reviewed scientific journals together with expert added interpretations.

The e-books are designed to make the latest research in the Five Bilingual BioMed e-Series – 37 volumes accessible to practicing health care professionals. These five e-Series cover the following medical specialties:

Cardiovascular diseases and therapies,

Genomics,

Cancer etiology and oncological therapies,

Immunology, and

Patient-centered precision medicine.

The material in these volumes can greatly enhance medical education and provide a resource for continued updating and education for health care professionals. In addition to the 37 e-books, LPBI has published more than 6,000 articles in its online scientific journal “PharmaceuticalIntelligence.com”, which has received 2.5 million views since its launch in 4/2012, Top articles had more than 18,000 views.

The Portfolio is:

rights‑clean,
expert‑curated healthcare corpus
mapped to a living Ontology,
already packaged for immediate model ingestion and
suitable for safe pre-training, evals, and fine‑tuning.

If healthcare domain data is on your roadmap, this is a rare, defensible asset worth a preview.

LPBI Group is offering transfer of ownership, in full, a privately held, multimodal healthcare training corpus leveraging propriety unique data set curated by domain experts and mapped to a living ontology for GenAI creating defensibility. It spans 6,250+ articles (~2.5MM views), 48 e‑books (EN/ES) (+151,000 page downloads), 100+ e‑proceedings with +50 tweet collections, 7,500+ biological images with expert context, and 300+ Audio podcasts on Life Sciences breakthroughs. Each asset has timestamps, author/role labels, crosslinks, and view histories. Rights are centrally assigned with explicit model‑training data by domain-aware for model implementation for Small LMs or LLMs. Metadata export exists; full text and media transfer via WordPress/Amazon account control for immediate ingestion.

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Full acquisition only: LPBI Group’s Healthcare Training Data Corpus

Scientific articles
e‑Books in Medicine
e‑Proceedings,
Biological images
Podcasts

#HealthcareAI #FoundationModels #TrainingData

Contact Founder: avivalev-ari@alum.berkeley.edu

PharmaceuticalIntelligence.com

About the Founder

LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director, INTERACTIVE CHAT with Grok, created by xAI

https://pharmaceuticalintelligence.com/2025/04/30/interactive-chat-with-grok-created-by-xai-lpbi-groups-legacy-and-biography-of-aviva-lev-ari-phd-rn-founder-director/

For Recognitions and a DETAILED BIO by Perplexity.ai and Gemini 2.5 Pro (experimental), see

“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)

https://pharmaceuticalintelligence.com/2025/04/29/show-thinking-by-ai-deep-research-the-ai-biography-description-of-aviva-lev-ari-phd-rn-founder-of-pharmaceuticalintelligence-com-by-perplexity-ai-and-by-googles-gemini-2/

Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma

On 11/14, 2025, Dr. Lev-Ari asked @Grok about AI Initiatives at a Big Pharma, i.e., Pfizer.

@Grok response is presented, below

URL SOURCE:

https://x.com/i/grok/share/0ol5VOJsEYs11baXq4xkzNb0h

Pfizer’s AI Initiatives Overview

Pfizer, a global pharmaceutical leader, has integrated artificial intelligence (AI) and machine learning (ML) across its operations to accelerate drug discovery, enhance clinical trials, improve manufacturing, and drive patient-centric innovations. These efforts aim to reduce development timelines, boost efficiency, and address challenges like rare disease detection. As of late 2025, Pfizer’s AI strategy emphasizes internal expertise, cloud-based tools (primarily with AWS), and cross-industry collaborations, with a focus on multimodal data analysis and generative AI. Below is a breakdown of key initiatives, drawn from recent developments.

1. Pfizer AI Cloud Transformation (PACT) Program Launched in 2021 with AWS, PACT is a prototyping accelerator for AI/ML applications in lab, clinical manufacturing, and supply chain efforts. It has pursued 14 projects, with five now in production. Key outcomes include:

Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis.

55% reduction in infrastructure costs through cloud optimization.

Exploration of virtual/augmented reality for training, with rapid prototyping to test feasibility. This program fosters “fail-fast” innovation, enabling quick iteration on ideas like AI-driven predictive modeling.

2. Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D, cutting years off traditional timelines (e.g., from 8–10 years to months for certain candidates).

COVID-19 Initiatives: AI optimized molecular searches for PAXLOVID (oral antiviral), enabling intravenous-to-oral pivots. During vaccine development, the Safety Data Quality (SDQ) tool—a custom AI for clinical trial data management—saved a full month of analysis via the Breakthrough Change Accelerator sandbox.

Precision Medicine and Subpopulation Identification: Advanced ML (classical and deep learning) analyzes molecular datasets from trials to predict patient responses, informing trial design, first-in-human studies, and oncology/inflammatory disease targeting. This has doubled clinical success rates to ~20% (vs. industry 7–10%).

ML Research Hub: Pfizer’s Cambridge, MA-based Biomedical Data Science group builds internal talent for AI in genome sciences, predicting disease outcomes and treatment efficacy using techniques from tech giants like Google.

3. Clinical Trials and Regulatory Efficiency AI automates content creation across the drug lifecycle, from lab data to regulatory docs and patient booklets, ensuring quality and speed.

Predictive Regulatory Tools: ML models forecast regulator queries, proactively addressing safety concerns to build trust and shorten approvals.

Decentralized Trials: The “Clinical Trial Anywhere” model uses AI to integrate remote data (e.g., home health visits), improving recruitment/retention and generating real-world evidence.

Inventory and Supply Chain: AI predicts vaccine storage issues, pioneered during COVID distribution.

4. Disease Detection and Diagnostics

ATTR-CM Initiative: Through the ASPIRE collaboration (with Amyloidosis Research Consortium), AI analyzes EHRs, ECGs, and echocardiograms to detect transthyretin amyloid cardiomyopathy earlier, targeting underdiagnosed heart failure cases.

Rare Diseases: ML models identify symptoms in large datasets, mapping the immune system for better predictions.

5. Generative AI and Operational Tools

Charlie Platform: Rolled out in 2024 for marketing, this gen AI tool (named after co-founder Charles Pfizer) generates compliant content like emails, presentations, and medical article drafts. Trained on approved product data, it streamlines physician targeting and customer insights.

Scientific Data Cloud: AWS-powered centralization of data/ML capabilities, enabling faster research and treating 1.3 billion patients in 2022. It supports gen AI via Amazon SageMaker/Bedrock for manufacturing efficiency.

Global Health Grants: Through the Pfizer Foundation’s AI Learning Lab, funding supports AI for equitable healthcare access, e.g., biometric tools for community care.

6. Partnerships and Education

Collaborations: With AWS for cloud AI; IMI Big Picture for a 3M-sample disease database; IIT Madras for the 2025 AIPM Symposium on AI in pharma (focusing on drug discovery and precision medicine).

Talent and Events: Hosting webinars on AI in manufacturing (e.g., predictive maintenance, regulatory submissions) and engaging leaders like Dr. Subha Madhavan on AI for biomedical data integration.

Strategic Focus: $500M R&D reinvestment by 2026 targets AI for productivity, part of $7.7B cost savings. Emphasis on ethical AI, diverse datasets, and competing with global biotech advances (e.g., China’s AI in CRISPR).

Pfizer’s approach balances operational efficiency with transformative R&D, positioning AI as a core enabler rather than a standalone focus. Ongoing investments, like cloud migrations saving $47M annually and reducing CO2 emissions, underscore sustainability. For the latest, monitor Pfizer’s investor updates or events like AWS re:Invent.

Responsiveness to Big Pharma AI Initiatives by LPBI Group’s Digital IP Portfolio:

Scientific articles
e‑Books in Medicine
e‑Proceedings,
Biological images
Podcasts

AI Initiative at Big Pharma

i.e., Pfizer

Composed @Grok

LPBI Group’s Digital IP Asset:

Journal articles

N = 6,250

Composed by Aviva Lev-Ari

Generative AI tools

that save scientists up to 16,000 hours annually in literature searches and data analysis.

Generative AI tools searching LPBI’s Proprietary data in addition to Public Domain data sources

Journal ONTOLOGY used to optimize context classification selected for search

Drug Discovery and Development Acceleration

Pfizer uses AI, supercomputing, and ML to streamline R&D timelines

– Run prompts by category of research on the following three dyads

– Run ML across categories of research for these three dyads

-Gene-disease

-Disease-drug

-Gene-drug

Clinical Trials and Regulatory Efficiency AI:

-Predictive Regulatory Tools

-Decentralize Trials

-inventory management

Curation competences:

content creation across the drug lifecycle, from lab data to regulatory docs

Disease Detection and Diagnostics:

– ATTR-CM Initiative

– Rare diseases

Heart Failure Diagnosis by Early detection of transthyretin amyloid cardiomyopathy

– Journal published ~30 curations by Dr. Larry on this subject ATTR-CM

– Run NLP on this Corpus

Rare diseases:

Journal published 560 articles on Rare diseases

– Run ML on this Corpus

Generative AI and Operational Tools:

– Charlie Platform

– Scientific Data Cloud AWS powered ML on centralized data

– Amazon’s SageMaker /Bedrock for Manufacturing efficiency

– Global Health Grants:

Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care

Content generated in the Journal can become “generated compliant content” if run on the Charlie Platform.

– For REUSE content in context

Entire Corpus of 9 Giga bytes can be ingested to Pfizer Foundation’s AI Learning Lab

– Run prompts against it

– Journal’s Content to be used for Internal staff expertise development

– Journal’s Content for Leadership development

Partnerships and Education

– Collaborations: IMI Big Picture for 3M – sample disease database

– AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine

– Webinars of AI for biomedical data integration

– Webinar on AI in Manufacturing

The Journal had published 547 articles in Precision Medicine

The Journal had published 1,114 articles in Drug Discovery

The Journal had published 701 articles in Drug Delivery

The Journal had published 3,615 articles on subject matter “Disease”

The Journal had published 738 articles on Biomedical topics

The Journal had published 425 articles on Artificial Intelligence (AI)

Strategic Focus:

– $500M R&D reinvestment by 2026 targets AI for Productivity

– Part of $7.7B cost savings

– Ethical AI, diverse DBs

– Global biotech advances: China’s AI in CRISPR

The Journal had published 432 articles on CRISPR

Productivity derived from Journal’s content:

– As a result of the fact that ~70% of the Journal’s articles are curations written by Domain Knowledge Experts subjectively expressing theirs clinical interpretations of basic and primary research – the productivity of the knowledge workers at any Big Pharma would increase vastly.

– If Grok and Claude would run on LPBI Group’s Digital IP Corpus, a scientific revolution will emerge

– It is not combinatorics applied to molecules with 98% futile results!!!

it is the IQ of Gifted HUMANS, of domain knowledge experts generating content using individual CREATIVITY no Quantum or Super Intelligence which is not in existence, YET.

– Foundation Models in Healthcare depends on the OUTPUT of the human creative mind. AI takes keyword (classic search) and concepts (semantic search) and run frequency of occurrence and predict the nest word, one word after the next one.

@@@@@@@

AI Initiative at Big Pharma

i.e., Pfizer

LPBI Group’s Digital IP Asset:

e-Books

Domain-aware Editorials and Curations

Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis.

The electronic Table of Contents of every e-book is a CONCEPTUAL MASTER PIECE of one unique occurrence in Nature generated by the Editor, or the Editors that had

– Commissioned articles for the e-Book

– Had selected articles from collections of Categories of Research created by domain knowledge experts

– Had reviewed the TOTALITY of the Journal’s Ontology and found new concept to cover in the e-Book not originally planned

Had incorporated Highlights of Lectures given at 100 Conferences LPBI Group’s Dr. Lev-Ari and Dr. Willians had cover in Real Real, by invitation, only as PRESS.

– The vision of the Editor-in-Chief of the BioMed e-Series reflects the BIG PICTURE of Patient care delivery.

– UC, Berkeley PhD’83

– Knowledge student and Knowledge worker, 10/1970 to Present

– Conceptual pioneer of 26 algorithms in Decision Science of Operations Management decision support systems

– 2005 to Present in the Healthcare field.

– 2005-2012: Clinical Nurse Manager in Post-acute SNF settings and Long-term Acute care Hospital Supervisor – had developed a unique view on Diagnosis, Therapeutics and Patient care delivery

– The BioMed e-Series is the EPITOM of human CREATIVITY in Healthcare an OPUS MAGNUM created by collaboration of top Scientists, Physicians and MD/PhDs

– The 48 e-Books Published by LPBI Group – represent the ONLY one Publisher on Amazon.com with +151,000 pages downloaded since the 1^st e-book published on 6/2013 and since Pay-per-View was launched by Amazon.com in 2016.

Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D timelines

Two volumes on the BioMed e-Series were subjected to Medical Text Analysis with AI, ML, Natural Language Processing (NLP).

– Cancer, Volume 1 (In English, part of the Spanish Edition, Series C)

– Genomics, Volume 2 (In English, part of the Spanish Edition, Series B)

– GPT capabilities are warranted to attempt to subject to ML Analytics every book of the MUTUALLY EXCLUSIVE 48 URLs provided by Amazon.com to LPBI Group, the Publisher.

– 5 URLs for 5 Bundles in The English Edition: Series A,B,C,D,E – English Edition

– All books in each series – 5 Corpuses for domain-aware Small Language Model in English

– All books in each series – 5 Corpuses for domain-aware Small Language Model in Spanish

– 5 URLs for 5 Bundles in The Spanish Edition: Series A,B,C,D,E –Spanish Edition

Clinical Trials and Regulatory Efficiency AI:

-Predictive Regulatory Tools

-Decentralize Trials

-inventory management

Disease Detection and Diagnostics:

– ATTR-CM Initiative

– Rare diseases

– No one had attempted ML on every book, only two books were analyzed by ML.

– No one had attempted ML on all the Volumes in any of the 5 Series.

– No one had attempted ML on all the 48 books

– WHEN that will be done – a REVOLUTION on Disease Detection and Diagnostics will be seen for the first time because the totality of these 48 books represent the Brains of Human Experts

Generative AI and Operational Tools:

– Charlie Platform

– Scientific Data Cloud AWS powered ML on centralized data

– Amazon’s SageMaker/Bedrock for Manufacturing efficiency

– Global Health Grants:

Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care

Add the content of all the Books to Charlie Platform

Partnerships and Education

Collaborations: IMI Big Picture for 3M – sample disease database

AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine

Webinars of AI for biomedical data integration

Webinard on Ai in Manufacturing

e-Books are the SOURCE for Education

– Offer the books as Partnership sustenance

Strategic Focus:

– $500M R&D reinvestment by 2026 targets AI for Productivity

– Part of $7.7B cost savings

– Ethical AI, diverse DBs

– Global biotech advances: China’s AI in CRISPR

URLs for the English-language Edition by e-Series:

Series A: Cardiovascular Diseases ($515)

https://www.amazon.com/gp/product/B07P981RCS?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks

Series B: Frontiers in Genomics ($200)

https://www.amazon.com/gp/product/B0BSDPG2RX?ref_=dbs_p_pwh_rwt_anx_b_lnk&storeType=ebooks

Series C: Cancer & Oncology ($175)

https://www.amazon.com/gp/product/B0BSDWVB3H?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks

Series D: Immunology ($325)

https://www.amazon.com/gp/product/B08VVWTNR4?ref_=dbs_p_pwh_rwt_anx_b_lnk&storeType=ebooks

Series E: Patient-Centered Medicine ($274)

https://www.amazon.com/gp/product/B0BSDW2K6C?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks

@@@@@@@

AI Initiative at Big Pharma

i.e., Pfizer

LPBI Group’s Digital IP Asset:

e-Proceedings: N = +100, and

Tweet Collections: N = +50

Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis.

Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D timelines

List of all e-Proceeding of +100 TOP Conferences in Biotech, in Medicine, in Genomics, in Precision Medicine

https://pharmaceuticalintelligence.com/press-coverage/part-two-list-of-biotech-conferences-2013-to-present/

In these conferences the Frontier of Science was presented, ofter BEFORE publication findings were revealed. These Proceedings are the ONLY written record of the events. They are privately-held, now for the first time available for Transfer of Ownership

The Tweet Collection are QUOTES of speakers on record. NOT ELSEWHERE available by name of speaker and affiliation

Clinical Trials and Regulatory Efficiency AI:

-Predictive Regulatory Tools

-Decentralize Trials

-inventory management

Disease Detection and Diagnostics:

– ATTR-CM Initiative

– Rare diseases

Generative AI and Operational Tools:

– Charlie Platform

– Scientific Data Cloud AWS powered ML on centralized data

– Amazon’s SageMaker/Bedrock for Manufacturing efficiency

– Global Health Grants:

Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care

Ingest to Charlie Platform ALL e-Proceedings of ALL Conferences

Apply GPT:

Training Data:

– One conference at a time

– All Conference on ONE subject matter, i.e., Immunotherapy, Oncolytic Virus Immunotherapy, Immune Oncology

Partnerships and Education

– Collaborations: IMI Big Picture for 3M – sample disease database

– AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine

– Webinars of AI for biomedical data integration

– Webinar on Ai in Manufacturing

Use Past Conference Agendas to build Future Conference Agendas

Use Speakers Lists to invite speakers/consultants to your events

Use topics covered in Conferences for Employee training & and in-house Leadership development

Strategic Focus:

– $500M R&D reinvestment by 2026 targets AI for Productivity

– Part of $7.7B cost savings

– Ethical AI, diverse DBs

– Global biotech advances: China’s AI in CRISPR

Having access to +100 e-Proceedings vs Not having access to this resource is a make or break in fine-tuning Corporate Branding: All your competitors attended and had sent Speakers

LPBI Group’s e-Proceedings is the only record in one URL

@@@@@@

AI Initiative at Big Pharmas i.e., Pfizer	LPBI Group’s Digital IP Asset: Biological Images selected by Experts embedded in original Text (Prior Art)
Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis.
Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D timelines	Gallery of ~8,000 Biological images and captions is a Treasure TROVE for scientific article writing, Presentation preparations. This Media Gallery is an Art collection of top Scholars in Medicine and Biology
Clinical Trials and Regulatory Efficiency AI: -Predictive Regulatory Tools -Decentralize Trials -inventory management
Disease Detection and Diagnostics: – ATTR-CM Initiative – Rare diseases	Gallery of ~8,000 Biological images and captions is a Treasure TROVE for Disease Detection and Diagnostics
Generative AI and Operational Tools: – Charlie Platform – Scientific Data Cloud AWS powered ML on centralized data – Amazon’s SageMaker/Bedrock for Manufacturing efficiency – Global Health Grants: Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care	Ingest into Charlie Platform the Media Gallery for generation of Medical article drafts
Partnerships and Education – Collaborations: IMI Big Picture for 3M – sample disease database – AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine – Webinars of AI for biomedical data integration – Webinar on Ai in Manufacturing
Strategic Focus: – $500M R&D reinvestment by 2026 targets AI for Productivity – Part of $7.7B cost savings – Ethical AI, diverse DBs – Global biotech advances: China’s AI in CRISPR

@@@@@@

AI Initiative at Big Pharma

i.e., Pfizer

LPBI Group’s Digital IP Asset:

Library of Audio and Video Podcasts

N = +300

Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis.

Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D timelines

Review ALL SCIENTIFIC BREAKTHROUGHS

Two criteria for Classifications used by Prof. Marcus W. Feldman and by Dr. Stephen J. Williams to generate the two classifications

https://pharmaceuticalintelligence.com/biomed-audio-podcast-library-lpbi-group/

Clinical Trials and Regulatory Efficiency AI:

-Predictive Regulatory Tools

-Decentralize Trials

-inventory management

Disease Detection and Diagnostics:

– ATTR-CM Initiative

– Rare diseases

Aviva Lev-Ari, PhD, RN, Stephen J. Williams, PhD and Prof. Marcus W. Feldman

Health Care Policy Analysis derived from the Farewell remarks from AMA President Jack Resneck Jr., MD | AMA 2023 Annual Meeting

LISTEN to Audio Podcast

Future of Medicine

https://pharmaceuticalintelligence.com/2023/06/10/health-care-policy-analysis-derived-from-the-farewell-remarks-from-ama-president-jack-resneck-jr-md-ama-2023-annual-meeting/

Generative AI and Operational Tools:

– Charlie Platform

– Scientific Data Cloud AWS powered ML on centralized data

– Amazon’s SageMaker/Bedrock for Manufacturing efficiency

– Global Health Grants:

Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care

Ingest to Charlie Platform all +300 Podcasts for Foundation’s AI Learning Lab

Partnerships and Education

– Collaborations: IMI Big Picture for 3M – sample disease database

– AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine

– Webinars of AI for biomedical data integration

– Webinard on Ai in Manufacturing

Use Podcast for Education
Use Podcast as Hybrid: Start presentation with a Podcast continue with a life interview

Examples of an Audio Podcast of Scientists on LPBI Group Team in the past:

Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/

Podcast with Prof. Marcus W. Feldman, PhD, Biology Department, Stanford University, Interview by Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-prof-marcus-w-feldman-phd-biology-department-stanford-university-interview-by-gail-s-thornton-phdc/

Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-sudipta-saha-phd-interview-by-gail-s-thornton-phdc-narrators-voice-gail-s-thornton-phdc/

Strategic Focus:

– $500M R&D reinvestment by 2026 targets AI for Productivity

– Part of $7.7B cost savings

– Ethical AI, diverse DBs

– Global biotech advances: China’s AI in CRISPR

Dr. Lev-Ari Prompted @Grok on 11/18/2025:

AI-Driven Cost Savings in Big Pharma

@Grok responded:

AI-Driven Cost Savings in Big PharmaArtificial intelligence (AI) applications across the pharmaceutical value chain—particularly in drug discovery, clinical trials, and operations—have the potential to generate substantial savings for major pharmaceutical companies (often referred to as “Big Pharma”). Based on recent industry reports and analyses from 2024-2025, these savings vary by application but could collectively reach tens of billions annually by the late 2020s. Projections indicate AI could add up to 11% in value relative to revenue for biopharma firms over the next five years through productivity gains and cost reductions. Below, I break down the estimated savings levels by key areas, drawing from credible sources like McKinsey, Deloitte, IQVIA, and others.

Clinical Trials

Annual Industry-Wide Savings: By 2030, AI integration into 60-70% of clinical trials could save the pharmaceutical industry $20-30 billion per year through faster timelines, better patient matching, and reduced administrative costs.
Per-Trial Cost Reduction: AI can cut trial costs by up to 70% and shorten durations by 80%, enabling quicker regulatory submissions (40% faster) with 50% improved cost efficiency. For example, AstraZeneca reported up to 25% shorter trial durations in cancer drug studies using AI for dose optimization and biomarker identification.
Specific Efficiency Gains: Feasibility surveys can see 90% time reductions using AI/ML tools.

Drug Discovery and Development

R&D Cost Drop: AI could reduce drug discovery costs by up to 40%, with overall development timelines shrinking from 5 years to 12-18 months (an 80% cut in some cases). From discovery to preclinical candidate stage, timelines can decrease by up to 50%.
Total Clinical Development Savings: Projected at $25 billion across the sector, driven by AI-accelerated pipelines.

Operations and Broader Impacts

Value Relative to Revenue: Biopharma AI investments may yield up to 11% additional value (e.g., via cost efficiencies and revenue growth) over five years. For related medtech segments, savings could hit 12% of total revenue within 2-3 years.
Operating Profits Boost: By 2030, AI could add $254 billion in annual operating profits industry-wide through productivity jumps (e.g., 50-100% in quality control) and lead time reductions (60-70%).
Time-to-Market: Up to 10% faster overall, with production KPIs improving revenue by 25%.

These estimates assume scaled adoption, with global AI spending in pharma rising from ~$3 billion in 2025 to $22-25 billion by 2027-2030. Challenges like high initial costs and data infrastructure may temper short-term gains, but early adopters (e.g., Pfizer, Novartis) are already seeing ROI. For context, the global pharma market is projected at $1.6 trillion by 2025, so even modest percentages translate to billions in savings. If you need details on a specific AI use case or company, let me know!

SOURCE

https://x.com/i/grok?conversation=1990851703051104519

Dr. Lev-Ari Prompted @Grok on 11/17/2025:

Pfizer, its competitors by size, market share, product lines and Investment in AI technologies

Grok responded

https://x.com/i/grok?conversation=1990458795936354506

Overview of Pfizer and Key CompetitorsPfizer is one of the world’s largest pharmaceutical companies, with a strong focus on innovative medicines and vaccines. Its primary competitors include Merck & Co., Johnson & Johnson (J&J), Roche, Novartis, and now AstraZeneca, based on revenue leadership and market overlap in areas like oncology, immunology, and vaccines. These companies dominate the global pharmaceutical industry, which is projected to reach $1.21 trillion in revenue by 2025. Below, I compare them across size (measured by 2024 revenue and employees), market share (approximate global pharma share based on 2024 revenues), product lines (key therapeutic areas and top products), and investments in AI technologies. Data reflects the latest available figures as of late 2025.

Here are the same comparisons with more concise tables (2024 data, latest available as of Nov 2025):

Size (2024 Revenue & Employees)

Company	Revenue (USD B)	Employees
Merck & Co.	64.2	70,000
Pfizer	63.6	88,000
Roche	~58.3	103,000
J&J (pharma only)	57.8	138,000
AstraZeneca	54.1	94,300
Novartis	~50.0	76,000

Approx. Global Pharma Market Share

Company	Share %
Merck & Co.	4.3
Pfizer	4.2
J&J / Roche	3.9
AstraZeneca	3.6
Novartis	3.3

Key Product Lines & Top Sellers (2024 revenue, USD B)

Company	Main Areas	Top Products (revenue)
Pfizer	Vaccines, cardiology, oncology	Eliquis (7.3), Prevnar (6.4), Vyndaqel (5.4)
Merck & Co.	Oncology, vaccines	Keytruda (25.0), Gardasil (8.6)
J&J	Immunology, oncology	Stelara (10.9), Darzalex (9.7)
AstraZeneca	Oncology, CVRM, respiratory	Farxiga (7.7), Tagrisso (6.6), Enhertu (4.0)
Roche	Oncology, neurology, hemophilia	Ocrevus (5.7), Hemlibra (4.0)
Novartis	Cardiology, immunology	Entresto (6.6), Cosentyx (5.2)

AI Investment Snapshot (2025)

Company	AI Highlights (2025)	Scale/Impact
Pfizer	AI cuts discovery from years → 30 days; heavy partnerships	Leader in adoption
AstraZeneca	Evinova AI trials unit; $2.5B AI Beijing hub; 12k+ staff upskilled	Very aggressive (>85% productivity gain)
Merck & Co.	Gen-AI for protocols; 20+ AI “blockbusters” in pipeline	>$1.2B spend
J&J	900+ AI projects → $500M savings; surgical AI training	Broad internal rollout
Roche	AI diagnostics + drug discovery; $55M Manifold Bio deal	Strong in diagnostics
Novartis	AI pipeline acceleration; data-science alliances	Integrated into $10B R&D

Dr. Lev-Ari’s Prompt:

AI in biotech startups

@Grok Response

https://x.com/i/grok?conversation=1990458795936354506

Searched for “(“AI” OR “artificial intelligence”) (“biotech” OR “biotechnology”) startup since:2025-01-01″

10 results

Show All (2)

AI in Biotech Startups:

2025 LandscapeArtificial Intelligence (AI) is revolutionizing biotech startups by accelerating drug discovery, optimizing clinical trials, and enabling personalized medicine. In 2025, AI applications like generative models for molecule design and predictive analytics for protein structures are slashing R&D timelines from years to months, reducing costs by up to 30%, and boosting success rates. The sector blends biology’s complexity with AI’s data-crunching power, drawing massive VC interest amid ethical debates on gene editing and biosecurity.Key Trends

Explosive Funding Growth: U.S. healthcare VC hit $23B in 2024, with ~30% ($5.6B) targeting AI-biotech—nearly triple 2023 levels. Biopharma startups raised $24.2B across 568 deals, up from $10.1B in 2023. Q3 2025 saw $97B global VC (up 38% YoY), half to AI firms. Mega-rounds ($100M+) surged, focusing on drug discovery and rare diseases.
Market Expansion: Global AI-biotech market: $4.6B in 2025, projected to $11.4B by 2030 (20% CAGR). Biotech overall to $5.85T by 2034 (13.6% CAGR), driven by AI in gene editing, microbiome therapeutics, and automation.
Compute Demands: Biotech AI requires massive GPUs; Nvidia’s AI sales hit $41.1B in one 2025 quarter (56% YoY). Startups lean on cloud partnerships (e.g., AWS-Recursion) or in-house clusters, with hyperscalers eyeing $3-4T infrastructure by 2030.
Regional Hotspots: North America leads (42% share) via FDA support and hubs like Boston/SF; Europe grows via funding/regulatory advances; Asia (e.g., China) via collaborations.
Challenges & Ethics: Selective funding favors clinically validated firms; rising M&A (big pharma acquiring AI startups); ethical scrutiny on AI gene editing (e.g., CRISPR enhancements).

Notable Startups & Recent Funding

Here’s a snapshot of standout AI-biotech startups, highlighting innovations and 2024-2025 funding:

Startup	Focus Area	Key Innovation	Recent Funding (2025)
Insilico Medicine	Drug Discovery	Generative AI for novel molecules	$100M+ Series D (ongoing)
Recursion Pharmaceuticals	Phenomics & Drug Repurposing	AI mapping diseases via cell images	$50M partnership w/ Nvidia
Absci Corp.	Protein Design	AI-generated antibodies/proteins	$20M from AMD (Jan 2025)
TandemAI	Drug Discovery	ML for molecular simulation	$22M Series A extension
Red Queen Bio	Biosecurity	AI for pathogen detection/design	$15M Seed led by OpenAI
Antiverse	Antibody Design	AI predicting antibody structures	Deal w/ Nxera Pharma (2024)
Deep Genomics	Genomics	AI extracting insights from DNA data	VC round undisclosed
Aizen Therapeutics	Molecule Generation	Proprietary AI engines for trials	Early-stage VC

These firms exemplify AI’s shift from hype to pipeline impact—e.g., Insilico’s AI-discovered drug entered Phase II trials in record time.Emerging ApplicationsAI’s top uses in biotech startups:

Drug Discovery: ML predicts drug-target interactions (e.g., AlphaFold-inspired tools cut screening costs 70%).
Genomics & Diagnostics: AI analyzes vast datasets for rare variants, powering precision oncology.
Clinical Trials: Predictive models optimize patient matching, reducing failures by 20-30%.
Synthetic Biology: AI designs custom microbes for therapeutics or biofuels.
Automation Labs: AI-robotics handle experiments autonomously, boosting throughput 10x.

Future Outlook

2025 signals a “quality over quantity” pivot: Investors prioritize AI startups with real-world data and partnerships (e.g., Y Combinator, Google for Startups). M&A will rise as big pharma (Pfizer, Merck) snaps up talent. Yet, compute shortages and regs (e.g., FDA AI guidelines) pose hurdles. For founders, blending AI with wet-lab validation is key to unlocking the next wave of breakthroughs—potentially curing diseases once deemed untreatable. If you’re building or investing, focus on

rare diseases or
oncology

for the hottest bets.

Additional Competitors by Product Line

@Grok Response

https://x.com/i/grok/share/Ple3W4IDlwhyjUwBUU4JAg2OD

Key Products and Focus AreasPfizer’s portfolio spans immunology, oncology, cardiology, endocrinology, neurology, and vaccines. In 2024, its top revenue generators included:

Eliquis (apixaban, blood thinner): $7.3 billion (11% of total revenue).
Prevnar family (pneumococcal vaccines): $6.4 billion (10%).
Paxlovid (COVID-19 antiviral): $5.7 billion (9%).
Vyndaqel (tafamidis, for rare heart disease): $5.4 billion (8%).
Comirnaty (COVID-19 vaccine): $5.3 billion (8%).
Ibrance (palbociclib, breast cancer drug): $4.3 billion (6%).

The company is investing heavily in AI-driven drug discovery (e.g., 2024 partnerships with NVIDIA and Saama) and next-gen therapies like RSV vaccines, gene therapies for muscular dystrophy, and oral GLP-1 drugs for obesity/diabetes. Challenges include patent expirations (e.g., Eliquis in 2026-2028) and biosimilar competition, but Pfizer’s diversified pipeline positions it for mid-single-digit growth in 2025.Pfizer’s Main CompetitorsPfizer operates in a highly competitive $1.5 trillion global pharma market, where rivals vie for dominance in oncology, vaccines, immunology, and emerging areas like obesity and gene therapy. Its primary competitors are fellow “Big Pharma” giants, often overlapping in therapeutic areas. Based on revenue, market share, and direct product rivalries, here are the top ones (ranked roughly by 2024 revenue for context):

Competitor	Headquarters	2024 Revenue (Pharma Segment)	Key Strengths & Overlaps with Pfizer	Notable Products
Johnson & Johnson (J&J)	New Brunswick, NJ, USA	$88.8 billion (total; pharma ~$57.8 billion)	Diversified (pharma, devices, consumer); strong in oncology, immunology, vaccines. Competes directly in blood thinners and cancer therapies.	Darzalex (multiple myeloma), Stelara (psoriasis), Imbruvica (blood cancer).
Merck & Co.	Rahway, NJ, USA	$64.2 billion	Oncology leader; vaccines and antivirals. Keytruda outsells Pfizer’s Ibrance; rivals in HPV/pneumococcal vaccines.	Keytruda (immunotherapy, $29.5 billion), Gardasil (HPV vaccine).
Roche Holding AG	Basel, Switzerland	~$68 billion (group; pharma ~$50 billion)	Diagnostics + pharma powerhouse; dominates oncology and neurology. Competes in antibody-drug conjugates post-Pfizer’s Seagen buy.	Ocrevus (MS), Hemlibra (hemophilia), Avastin (cancer).
AbbVie Inc.	North Chicago, IL, USA	$56.3 billion	Immunology and neuroscience focus; biosimilars erode shared markets like Humira vs. Pfizer’s Enbrel alternatives.	Humira (rheumatoid arthritis), Skyrizi (psoriasis), Rinvoq (arthritis).
Novo Nordisk A/S	Bagsværd, Denmark	~$40 billion (est.)	Diabetes/obesity specialist; exploding GLP-1 demand challenges Pfizer’s emerging obesity pipeline.	Ozempic/Wegovy (semaglutide for diabetes/weight loss).
Eli Lilly and Co.	Indianapolis, IN, USA	~$45 billion (est.; projecting $58-61 billion in 2025)	Diabetes/obesity and neurology; Mounjaro rivals Pfizer’s danuglipron in GLP-1 space.	Mounjaro/Zepbound (tirzepatide), Verzenio (breast cancer).
AstraZeneca PLC	Cambridge, UK	$50.95 billion	Oncology, respiratory, and cardiovascular; Tagrisso competes with Pfizer’s Lorbrena in lung cancer.	Tagrisso (lung cancer), Farxiga (diabetes/heart), Imfinzi (immunotherapy).
Novartis AG	Basel, Switzerland	~$48 billion	Gene therapy and immunology; rivals in rare diseases and oncology.	Cosentyx (psoriasis), Entresto (heart failure), Kisqali (breast cancer).
Bristol-Myers Squibb (BMS)	New York, NY, USA	$47.8 billion	Oncology and immunology; Opdivo directly competes with Pfizer’s Bavencio in checkpoint inhibitors.	Opdivo (immunotherapy), Eliquis (co-developed with Pfizer, but BMS handles ex-US).
Sanofi S.A.	Paris, France	~$46 billion	Vaccines and rare diseases; Dupixent challenges in immunology; rivals Prevnar in pneumococcal vaccines.	Dupixent (atopic dermatitis), Lantus (diabetes).

These competitors collectively hold over 50% of the global pharma market share. Emerging threats include biotech upstarts like Moderna (mRNA vaccines, directly rivaling Comirnaty) and generics firms like Teva (eroding post-patent revenues). In 2025, competition intensifies in obesity (Novo/Lilly lead) and oncology (Merck/Roche dominate), with tariffs and pricing pressures (e.g., US executive orders) affecting all.Pfizer’s edge comes from its scale and partnerships (e.g., BioNTech for mRNA), but it must navigate revenue dips from COVID fade-out and biosimilars. For 2025 projections, analysts expect 6-9% growth across the sector, with Pfizer targeting modest gains through oncology expansions. If you’d like deeper dives on specific rivals, financials, or products, let me know!

AI Acquisitions by Big Pharma

BioKnow67,888 followers

2 days ago • Visible to anyone on or off LinkedIn

AI in Pharma: From Tool to Value Creator 🚀

Over the past 5 years, pharma’s AI footprint has expanded rapidly and the investment trends tell a clear story.

💡 ~60% of collaborations and acquisitions now focus on TargetDiscovery and Validation — pharma’s main frontier to shorten early-stage R&D timelines and boost success rates through PrecisionBiology.
⚗️ The second-largest area (~25%) centers on AI-driven DrugDesign and MoleculeOptimization, where algorithms accelerate CandidateSelection, refine molecular properties, and enable NewModalities such as Biologics and CellAndGeneTherapies.
🏆 Among top players, Eli Lilly and Company stands out as the most active investor — making AI a true StrategicCapability, not just another research tool.

The takeaway?
AI isn’t just supporting pharma anymore, it’s reshaping it.

Source: Bita Sehat, PhD, MBA

hashtagai hashtaglifesciences hashtagpharmaceuticals hashtagtechbio hashtagbiotech

table

SOURCE

https://www.linkedin.com/feed/

Article was summarized by @Grok on 11/29/2025

@Grok SOURCE

https://x.com/i/grok?conversation=1994903972553855362

Summary of the Article:

“Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma”

This November 15, 2025, article on PharmaceuticalIntelligence.com (curated by LPBI Group) makes a compelling case for leveraging LPBI’s decade-plus of expert-curated digital IP as a high-fidelity, rights-clean training corpus to supercharge AI-driven innovation in Big Pharma. It contrasts the limitations of generic LLMs (like GPT) with the need for domain-specific, ontologized biomedical data, positioning LPBI’s assets as a “defensible moat” for accelerating R&D in drug discovery, precision medicine, and beyond. The piece blends market analysis of pharma giants with a deep dive into LPBI’s portfolio, emphasizing its multimodal, metadata-rich structure for NLP, knowledge graphs, and fine-tuning SLMs/LLMs.IntroductionThe thesis: In an era where AI investments in pharma (e.g., Eli Lilly’s aggressive funding) focus on slashing R&D timelines by 60%+ in target discovery and 25% in drug design, LPBI’s proprietary corpus—built since 2012 via human curation, digitization, and ontology mapping—offers unmatched authenticity over web-scraped data. It addresses GPT’s biomedical shortcomings (e.g., failing to infer fusion proteins or noncanonical pathways without curated inputs) and highlights LPBI’s foresight in text analysis for generative AI augmentation. A key quote from Data2Discovery: “We are able to improve drug discovery now as well as demonstrating new fast-cycle AI-driven processes that will have a revolutionary impact on drug discovery if fully implemented.”Portfolio OverviewLPBI’s ~9 GB, debt-free, multimodal corpus is privately held, expert-curated (e.g., by Prof. Marcus W. Feldman and Dr. Stephen J. Williams), and ingest-ready for AI pre-training/evaluations. It spans five key asset classes, each with metadata exports, timestamps, crosslinks, and centralized rights for model training:

Asset Class	Description & Size	Unique Value Proposition
I: Scientific Articles	6,250+ articles on PharmaceuticalIntelligence.com (~2.5M views); covers genomics, oncology, immunology, etc.	Live ontology, author/role labels, view histories; enables temporal NLP for trend analysis.
II: e-Books	48 bilingual (English/Spanish) volumes in 5 BioMed e-Series (e.g., Series A: Cardiovascular, 6 vols., $515 total; Series E: Patient-Centered, 4 vols., $274); 151,000+ page downloads; 2,728 articles.	Peer-reviewed, senior-editor TOCs; pay-per-view model proves demand; ideal for entity-relationship extraction.
III: e-Proceedings	100+ from biotech/genomics conferences (2013–2025); +50 tweet collections as speaker quotes with affiliations.	Real-time event curation; captures emerging insights for knowledge graph augmentation.
V: Biological Images	7,500+ images in Digital Art Media Gallery; embedded as prior art in texts.	Expert-contextualized visuals; supports multimodal AI for image-text pairing in diagnostics.
X: Audio Podcasts	300+ interviews with scientific leaders (e.g., Nobel laureates like Jennifer Doudna); classified by themes like CRISPR, mRNA vaccines.	Transcripts + NLP WordClouds; adds auditory/verbal depth for voice-enabled AI copilots.

The portfolio’s “living ontology” allows seamless integration into tools like InfraNodus for concept mapping.AI Training RelevanceUnlike PubMed’s unstructured dumps, LPBI’s assets are pre-annotated for concept extraction (e.g., gene-disease-drug dyads), reducing hallucinations and bias in LLMs. A case study integrates curation with ChatGPT-5: Manual ontology + knowledge graphs uncovered novel WNT/Hedgehog interactions in lung cancer, generating research questions like: “How does the interaction between [[EGFR]] mutations and sex-specific gene alterations, including [[RBM10]], influence treatment outcomes in lung adenocarcinoma?” This hybrid approach outperforms solo GPT, proving the corpus’s role in trustworthy biomedical inference.Applications

Drug Discovery: ML prompts on dyads to mimic Pfizer’s AI (e.g., reducing discovery from years to months); supports biologics/cell therapies.
Precision Medicine: 547 articles for patient subtyping; 3,615 disease-focused pieces for predictive modeling.
Diagnostics & Rare Diseases: 560 rare disease articles + 30 on ATTR-CM for early detection (e.g., via Pfizer’s ASPIRE AI).
Clinical/Regulatory: Streamlines trials, evidence synthesis, and content generation (e.g., via Pfizer’s “Charlie” copilot, saving hours on lit reviews).
Generative Tools: Fine-tune for compliant, domain-aware outputs in medical affairs/safety.

Challenges & Solutions

Data Quality/Bias: Unstructured text leads to GPT errors; solved by expert curation + ontology for accurate, diverse inputs.
Regulatory Compliance: Rights fragmentation; addressed via LPBI’s centralized assignment for NDA-secure licensing.
Scalability: Generic data overload; LPBI’s focused, high-signal corpus enables fast-cycle AI without noise.

Recommendations

Urge Big Pharma (e.g., Pfizer, Merck—table highlights Merck’s $64.2B revenue, Keytruda focus) to acquire the full portfolio for end-to-end knowledge bases, or license under NDA for SLM/LLM training (English/Spanish).

Emphasizes “buy the moat” for competitive edge in 2025’s 6–9% sector growth (obesity/oncology hotspots).

Contact: avivalev-ari@alum.berkeley.edu.

Conclusion

LPBI’s corpus isn’t just data—it’s a “scientific revolution enabler,” blending human creativity with AI for transformative pharma impact. Validated on extraction tasks, it’s primed for partnerships, outshining combinatorial predictions with authentic, curated depth. This article builds on prior LPBI mappings (e.g., our podcast TOC summary), reinforcing the portfolio’s strategic fit for AI.

For deeper analysis or related assets, let me know!

Read Full Post »

LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director – INTERACTIVE CHAT with Grok, created by xAI

Posted in BioMed e-Books e-Series by LPBI Group, LPBI Group Founder - Aviva Lev-Ari, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, LPBI Management on April 30, 2025| 1 Comment »

LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director – INTERACTIVE CHAT with Grok, created by xAI

Reporter: Aviva Lev-Ari, PhD, RN

I am not Grok 3, I am Grok, created by xAI. However, I can certainly provide you with the biography of Aviva Lev-Ari, PhD, RN, as an interactive chat. Here it is:

https://askgpt.app/chat/9ecd37d5-8e7c-4c36-9879-1a67218437dd

THIS INTERACTIVE CHAT with xAI WAS EDITED and APPROVED by Aviva Lev-Ari, PhD, RN on 4/30/2025. She had approved all the edits provided by Prof. Marcus W. Feldman, Stanford University.

User:

Can you provide a comprehensive biography of Aviva Lev-Ari, PhD, RN, highlighting her career, achievements, and future aspirations?

Grok:

Certainly! Here is a detailed biography of Aviva Lev-Ari, PhD, RN, showcasing her remarkable journey and contributions to the field of pharmaceutical intelligence:

Aviva Lev-Ari, PhD, RN: The Trailblazing Innovator of Pharmaceutical Intelligence

In the world of pharmaceutical intelligence, Aviva Lev-Ari, PhD, RN, is a true trailblazer. On May 21, 2025, as Aviva celebrates her 75th birthday, she reflects on her illustrious career and looks forward to the enduring legacy of the LPBI Group, particularly its role in advancing the Multimodal Healthcare Foundation Model. https://pharmaceuticalintelligence.com/healthcare-foundation-model/

Aviva’s journey has been marked by relentless innovation and a deep commitment to enhancing scientific communication and education by developing methods for (a) mitigating scientific information overload by curations, and (b) mitigating the perishability of scientific information by continual information updating. As she looks back, she takes pride in the over 6,200 scientific articles and 48 books produced by her and her team, which have reached and educated a global audience. The impressive statistics of the PharmaceuticalIntelligence.com Journal, with over 2.3 million views and 1.5 million visitors, are a testament to the impact of her work.

Looking forward, Aviva is excited about the future of the LPBI Group’s intellectual property as training data for the Multimodal Healthcare Foundation Model. This model represents the next frontier in healthcare AI, promising to leverage the team’s extensive knowledge to improve healthcare delivery and understanding its complexities. Aviva envisions a future where their work continues to drive innovation, shaping the way healthcare professionals and technologies interact and evolve.

As she celebrates this milestone, Aviva remains committed to mentoring the next generation and fostering collaboration across the industry. Her legacy, intertwined with the LPBI Group’s contributions, will continue to inspire and lead the way in pharmaceutical intelligence and healthcare online education for years to come.

Looking to the future, Aviva and her team’s intellectual property, encompassing their vast repository of scientific articles, e-books, images, podcasts, and conference proceedings, will serve as crucial training data for building a Multimodal Healthcare Foundation Model. This innovative approach, as outlined on https://pharmaceuticalintelligence.com/healthcare-foundation-model/, will leverage her team’s expert knowledge to enhance healthcare AI technologies, promising to revolutionize the way healthcare is delivered and understood. By integrating their extensive content into AI training datasets, Aviva and her team are poised to lead the next wave of advancements in healthcare, ensuring that their legacy continues to drive progress and innovation.

Beyond her professional achievements. As a mentor and collaborator, she has inspired a new generation of experts, nurturing their talents and guiding them towards new career goals reaching new heights. Cases-in-point are Adam Sonnenberg and Madison Davis (see their profile on LinkedIn and their roles at LPBI Group).

In the vast landscape of healthcare and pharmaceuticals, one name stands out as a beacon of innovation and expertise: Aviva Lev-Ari, PhD, RN. With a career, spanning for decades, Aviva has left an indelible mark on the e-Scientific Publishing industry, revolutionizing the way we approach electronic scientific publishing, knowledge communication and online education.

Born with an insatiable curiosity and a passion for understanding the intricacies of social sciences already in her high school years then intricacies of the healthcare field, in her 50s, Aviva embarked on an educational journey that would shape her future. From her early days at The Hebrew University of Jerusalem, where she earned her BA in 1973 and MA in 1976, a former student of Professor Louis Guttman, to her groundbreaking PhD in Industrial Organization Economics with a focus on corporate organizational aspects and Economic Geography at the University of California, Berkeley in 1983 where she was an advisee of Professor Allan Pred. Aviva’s thirst for knowledge knew no bounds. Along the way, she honed her skills at the Stanford University Graduate School of Business during an exchange program with UCB from 1980 to 1981 and studied with Professor James March.

Her career from 1985 to 2005 saw her working with some of the most notable organizations in various capacities. Among her employers during this period were:

SRI, Menlo Park, CA: The largest Think Tank in the US with global reach, where Aviva served as Program Director, Business and Economic Statistics
Amdahl Corporation, acquired by Fujitsu, Japan, where Aviva was a Senior Scientist, Lead, Demand Forecasting.
Monitor Company, acquired by Deloitte, where Aviva worked as a Senior Consultant in Cambridge, MA, John Hancock account.
MITRE, the most prestigious Federally Funded Research and Development Center (FFRDC), where Aviva was Head of Research of Economic and Decision Analysis Center (EDAC) in Bedford, MA.
Perot Systems Corporation, acquired by Dell Technologies, where Aviva served as Director of Advanced Information Systems in Cambridge, MA.
McGraw Hill, a global publisher, where Aviva was Director of Research Methods at CTB/McGraw-Hill in Monterey, CA.

25 years later she obtained her healthcare education and nursing credentials at Northeastern University’s Bouvé College of Health Sciences in 2007.

Armed with a formidable intellect and a visionary spirit, Aviva set out to transform the world of pharmaceutical intelligence in 2012 following five years in Clinical Nursing Management.

As the founder and director of the LPBI Group, launched in 4/2012, she created the BioMed e-Series, a cutting-edge e-learning platform that has empowered countless healthcare professionals to reach new heights in their careers. Through her role as Editor-in-Chief of Leaders in Pharmaceutical Business Intelligence, LPBI Group’s (a) Journal PharmaceuticalIntelligence.com and (b) BioMed e-Series Aviva has been at the forefront of electronic scientific publishing and content curation, driving innovation and fostering collaboration across the industry.

Aviva’s contributions to the field are nothing short of remarkable. With her extensive body of work, including numerous scientific articles, and e-books, she has shed light on critical topics such as cardiovascular diseases, pharmaco-genomics and cancer therapies. Her research interests span a wide range of disciplines, from medical, pharmaceutical, life sciences and scientific communications to health policy and healthcare delivery, showcasing her unwavering commitment to advancing the frontiers of knowledge by creation of curations that include creative interpretations of scientific findings.

The impact of Aviva’s work is evident in the impressive statistics of PharmaceuticalIntelligence.com, which, as of April 27, 2025, has garnered over 2,368,774 views and 1,506,446 visitors. The platform features 6,227 posts, of which 3,653 are curated by Aviva herself, reflecting the depth and breadth of her contributions. Aviva and her team at Leaders in Pharmaceutical Business Intelligence Group, LLC, doing business as LPBI Group, Newton, MA, have produced over 6,200 scientific articles (posts) and published 48 volumes, showcasing the extensive knowledge and expertise they bring to the field.

Her key team members include Larry H. Bernstein, MD, FACP, Justin D. Pearlman, MD, PhD, FACC, Stephen J. Williams, PhD, Tilda Barliya, PhD, Sudipta Saha, PhD, Dror Nir, PhD, Demet Sag, PhD, Ritu Saxena, PhD, Gail S Thornton, PhD (c), and Irina Robu, PhD. Together, they have created 48 volumes of e-books, with over 150,000 pages downloaded from these e-books on Amazon.com, showcasing the global reach and influence of their work. The BioMed e-Series, accessible at https://pharmaceuticalintelligence.com/five-bilingual-biomed-e-series/ further exemplifies their commitment to providing comprehensive knowledge and educational resources.

Aviva’s multimedia approach to scientific communication is highlighted by the inclusion of 7,074 biological images, 302 podcasts, over 100 e-proceedings for biotech and medical conferences, and more than 50 tweet collections. These resources have enriched the learning experience for professionals worldwide, making complex scientific concepts more accessible and engaging.

The future looks bright, Aviva and her team’s intellectual property, encompassing their vast repository of scientific articles, e-books, images, podcasts, and conference proceedings, will serve as crucial training data for building a Multimodal Healthcare Foundation Model. This innovative approach, as outlined on https://pharmaceuticalintelligence.com/healthcare-foundation-model/, will leverage their expert knowledge to enhance healthcare AI technologies, promising to revolutionize the way healthcare is delivered and understood. By integrating their extensive content into AI training datasets, Aviva and her team are poised to lead the next wave of advancements in healthcare, ensuring that their legacy continues to drive progress and innovation.

As a mentor and collaborator, Aviva has inspired a new generation of experts, nurturing their talents and guiding them towards success in the Era of Artificial Intelligence and Medicine, Pharmaceutical, Healthcare and Life Sciences.

For Recognitions and a DETAILED BIO by Perplexity.ai and Gemini 2.5 Pro (experimental), see

“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)

https://pharmaceuticalintelligence.com/2025/04/29/show-thinking-by-ai-deep-research-the-ai-biography-description-of-aviva-lev-ari-phd-rn-founder-of-pharmaceuticalintelligence-com-by-perplexity-ai-and-by-googles-gemini-2/

APPENDIX

CV Format

https://www.linkedin.com/in/avivalevari/

Publication List

Read Full Post »

“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)

Posted in LPBI Group Founder - Aviva Lev-Ari, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, LPBI Management on April 29, 2025| Leave a Comment »

“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)

Reporter: Aviva Lev-Ari, PhD, RN

ADDED by Aviva Lev-Ari, PhD, RN on 5/2/2025

CV Format – Not by AI

https://www.linkedin.com/in/avivalevari/

Publication List – Not by AI

Updated on 4/30/2025

For a SYNOPSIS by xAI, see

LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director, INTERACTIVE CHAT with Grok, created by xAI

https://pharmaceuticalintelligence.com/2025/04/30/interactive-chat-with-grok-created-by-xai-lpbi-groups-legacy-and-biography-of-aviva-lev-ari-phd-rn-founder-director/

Updated on 4/30/2025

Below, please find Edited and Approved by Aviva Lev-Ari, PhD, RN on 4/29/2025

Bio Version 1, 4/19/2025, Perplexity.ai
Bio Version 2, 4/29/2025, Perplexity.ai AND Gemini 2.5 Pro (experimental)

Perplexity.ai – my “ask” produced

Bio Version 1, 4/19/2025

https://www.perplexity.ai/search/686cec2f-7a11-4f3d-9c8b-8a5c80f3282a#12

and

https://www.perplexity.ai/search/686cec2f-7a11-4f3d-9c8b-8a5c80f3282a?12=r

Can you write a Profile for “Aviva Lev-Ari, PhD, RN” for an entry in Wikipedia with the reference style they require?

Answer

Sources

pharmaceuticalintelligence

pharmaceuticalintelligence.com/contributors-b…

Aviva Lev-Ari, PhD, RN, Director and Founder

BIO. 1985 – 2005, Aviva Lev-Ari worked at Director Level with Start-ups and Fortune 100 companies making presentations at the CEO Board Room level …

linkedin.com/in/avivalevari

Aviva Lev-Ari, PhD, RN – Leaders in Pharmaceutical … – LinkedIn

Dr. Aviva Lev-Ari, Ph.D., RN, is an important innovator in the domain of electronic scientific publishing.

muckrack

muckrack.com/aviva-lev-ari-…

Aviva Lev-Ari’s Profile | MedTech Intelligence Journalist – Muck Rack

Find Aviva Lev-Ari of MedTech Intelligence’s articles, email address, contact information, Twitter and more.

American Friends of the Hebrew University

afhu.org/2018/05/03/avi…

Aviva Lev-Ari – American Friends of the Hebrew University

Aviva Lev-Ari (nee Abraham) began her studies at Hebrew University in 1970 in geography and history, and later received her master’s degree in the Urban

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

pharmaceuticalintelligence.com/knowledge-port…

Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

Aviva Lev-Ari, PhD, RN Director & Founder Leaders in Pharmaceutical Business Intelligence (LPBI) Group UPDATED on 12/26/2023 On 12/24/2023 Published: Contributions to Biological Sciences by Sci…

LinkedInEditors

linkedin.com/pulse/etiologi…

Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and …

by Aviva Lev-Ari, PhD, RN – Editor-in-Chief, LPBI Group, BioMed e-Series LINKs to other e-Books on Heart Disease on Amazon.com by Our Team · Cardiovascular Diseases, Volume One: Perspectives on Nitric Oxide in Disease Mechanisms, on Amazon.

en.wikipedia.org

en.wikipedia.org/wiki/Help:Cita…

Help:Citation Style 1 – Wikipedia

Citation Style 1 (CS1) is a collection of reference citation templates that can be modified to create different styles for different referenced materials.

linkedin.com/posts/avivalev…

Aviva Lev-Ari, PhD, RN – Founder’s Bio – LinkedIn

Aviva Lev-Ari, PhD, RN Founder 1.0 LPBI and 2.0 LPBI at Leaders in Pharmaceutical Business Intelligence Group, LLC

pharmaceuticalintelligence.com

Aviva Lev-Ari, PhD, RN, Director and Founder

Aviva Lev-Ari, PhD, RN

Aviva Lev-Ari (born 1950) is an Israeli-American scientist, editor, and entrepreneur known for her contributions to scientific publishing, biomedical innovation, and interdisciplinary research in cardiovascular and cancer medicine. She is the founder and Director of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group and serves as Editor-in-Chief of the open access scientific journal PharmaceuticalIntelligence.com and the LPBI BioMed e-Series.1 2 5

Early Life and Education

Lev-Ari began her academic studies at the Hebrew University of Jerusalem in 1970, earning a master’s degree in Urban Studies. She later worked as a Research Associate at the Technion – Israel Institute of Technology and completed her PhD at the University of California, Berkeley in 1983. After a 25-year career in applied research and management consulting with start-ups and Fortune 100 companies, she pursued further studies in biological sciences, nursing, and pharmacology at Northeastern University, earning a nursing degree in 2007.4 5

Career

Lev-Ari’s professional career spans academia, industry, and healthcare. She has held director-level positions in both start-ups and major corporations, and served as Director of Research at McGraw-Hill/CTB. In 2012, she launched PharmaceuticalIntelligence.com, which has published over 5,900 scientific articles and received more than 1.9 million views by 2020.5

Update on 5/2/2025

As of April 27, 2025, the Journal PharmaceuticalIntelligence.com has garnered

over 2,368,774 views and

1,506,446 visitors.

the platform features 6,227 posts

of which 3,653 are curated by Aviva Lev-Ari, PhD, RN

As founder and director of LPBI Group, Lev-Ari has led the development of innovative methodologies for scientific curation, real-time conference reporting, and digital publishing. She is recognized as a Key Opinion Leader in cardiovascular disease, cancer research, genomics, and medical text analysis using artificial intelligence and natural language processing.2 5

Publications

Lev-Ari is the editor and co-author of multiple volumes in the LPBI BioMed e-Series, including a six-volume set on cardiovascular diseases covering topics such as nitric oxide mechanisms, genetics, pharmacotherapies, and interventional cardiology.2 5 She has also overseen volumes on cancer biology, genomics, and precision medicine. Her editorial leadership extends to hardcover publications and curated reports on emerging trends in biomedical science.2 5

Research and Innovation

Lev-Ari’s research has addressed the genetics and epigenetics of cardiovascular disease, the development of combination drug therapies, and the integration of genomics into personalized medicine. She has contributed to the understanding of biomarkers, risk prediction, and therapeutic strategies in both cardiovascular and oncological contexts.5 6

Professional Recognition

Lev-Ari has served as an elected advisor to the Governing Board of the Massachusetts Academy of Sciences and has been recognized for her contributions to scientific communication and education.2

References

“Aviva Lev-Ari, PhD, RN, Director and Founder.” PharmaceuticalIntelligence.com. https://pharmaceuticalintelligence.com/contributors-biographies/aviva-lev-ari/
“Aviva Lev-Ari, PhD, RN – Leaders in Pharmaceutical Business Intelligence Group.” LinkedIn. https://www.linkedin.com/in/avivalevari
“Aviva Lev-Ari’s Profile.” Muck Rack. https://muckrack.com/aviva-lev-ari-rn
“Aviva Lev-Ari.” American Friends of the Hebrew University. https://www.afhu.org/2018/05/03/aviva-lev-ari/
“Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0.” PharmaceuticalIntelligence.com. https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/aviva-lev-ari-phd-rn-founder-lpbi-group-1-0-2-0/
“Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics.” LinkedIn. https://www.linkedin.com/pulse/etiologies-cardiovascular-diseases-epigenetics-lev-ari-phd-rn

This article uses citation style 1 as recommended by Wikipedia guidelines.

Perplexity.ai BIO Version 1, 4/19/2025

https://www.perplexity.ai/search/686cec2f-7a11-4f3d-9c8b-8a5c80f3282a?12=r

Perplexity.ai suggests answers for AI-created questions:

What do you know about “Aviva Lev-Ari, PhD, RN”
Images of “Aviva Lev-Ari, PhD, RN”
What are some of the most popular articles curated by Aviva Lev-Ari
What are the most cited articles by Aviva Lev-Ari
What are the main topics covered in Aviva Lev-Ari’s most cited articles
How does Aviva Lev-Ari’s work in cancer etiology compare to her work in immunology
Comparison of Aviva Lev-Ari’s Work in Cancer Etiology vs. Immunology
What specific areas of cancer etiology has Aviva Lev-Ari focused on
What are the most recent publications by Aviva Lev-Ari on cancer
How does Aviva Lev-Ari’s research address the role of genetics in cancer development
What about her work in Cardiovascular? Books on Amazon?
How did Aviva Lev-Ari’s background in nursing influence her career in pharmaceutical intelligence
How did Aviva Lev-Ari’s nursing career prepare her for her role in electronic scientific publishing
In what ways did Aviva Lev-Ari’s nursing career shape her understanding of healthcare delivery and its application in scientific publishing

Related

How did Aviva Lev-Ari’s nursing experience influence her approach to multidisciplinary team collaboration

What challenges did Aviva Lev-Ari face when transitioning from nursing to pharmaceutical intelligence

How did Aviva Lev-Ari’s nursing background impact her advocacy for the nursing profession

What specific nursing roles did Aviva Lev-Ari hold that shaped her career in scientific publishing

Perplexity.ai – Aviva’s “ask” produced

Bio Version 2, 4/29/2025

https://www.perplexity.ai/search/i-wish-to-get-a-description-an-KfyRhnOWSmWDJ3DNGY0MoA?0=d

Aviva Lev-Ari, PhD, RN, is a distinguished innovator in electronic scientific publishing, biomedical knowledge curation, and medical education. She is the founder and director of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, a pioneering organization in digital scientific publishing and medical text analysis1 4. Her career bridges academia, industry, and healthcare, with significant contributions to knowledge dissemination and the development of new methodologies for scientific curation.

Professional Background

Founder & Director, LPBI Group: Dr. Lev-Ari established LPBI Group in 2012, initially as an electronic scientific publisher and later evolving it into a platform for medical text analysis using NLP, machine learning, and AI. The group also explores content monetization strategies such as blockchain1 2.
Scientific Publishing: She serves as Editor-in-Chief of the open-access journal PharmaceuticalIntelligence.com, which has published thousands of scientific articles and curated content in medicine and life sciences. The journal and its associated BioMed e-Series have reached in 2020 over 1.7 million readers and are widely used by professionals globally1 4.

As of April 27, 2025, the Journal PharmaceuticalIntelligence.com has garnered

over 2,368,774 views and

1,506,446 visitors

BioMed e-Series: Dr. Lev-Ari led the creation and editing of multi-volume e-book series in five medical specialties: cardiovascular diseases, genomics, cancer and oncology, immunology, and precision medicine. These e-books are available on Amazon and have been translated into Spanish to expand their reach1 2 4. See

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

Conference Coverage: She has served as an invited press/media professional at more than 70 global conferences, producing real-time e-proceedings and tweet collections that are cited in journal articles and books2 4. See

https://pharmaceuticalintelligence.com/press-coverage/

Research and Clinical Experience: Her expertise includes cardiovascular pharmacology and therapy research, drug discovery, and long-term acute care nursing management, with roles at institutions such as Northeastern University and various hospitals in Massachusetts1 4 5. See, all clinical positions:

Scientific and Medical Affairs Chronological CV

Academic and Industry Experience

Education: Dr. Lev-Ari began her academic journey at Hebrew University, later earning a PhD from the University of California, Berkeley. She also completed studies in biological sciences, nursing, and pharmacology at Northeastern University5.
Industry Roles: She has worked with start-ups and Fortune 100 companies as a management consultant and executive, contributing to algorithm-based decision support systems and electronic commerce analytics4 5.

Recognitions and Innovations

Medical Education: Nominated for the 2018 Yidan Prize for her work in developing scientific content curation methodologies4.
Intellectual Property: Creator of three intellectual property asset classes in scientific publishing and knowledge curation4.
Methodology Development: Innovator in electronic Table of Contents (eTOCs) creation and real-time press coverage using social media for scientific conferences4.
Elected advisor to the Governing Board of the Massachusetts Academy of Sciences and has been recognized for her contributions to scientific communication and education.2

On 8/17/2018, Dr. Lev-Ari, PhD, RN was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board.

http://www.maacadsci.org

MAS FELLOWS

GOVERNING BOARD

ACTIVITIES

Recognitions ADDED by Aviva Lev-Ari, PhD, RN

2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19 via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19
- By “Mentions” – Ranked #4: @pharma_BI and
- By “Tweets” – Ranked #2: @AVIVA1950
via NodeXL http://bit.ly/2KB6cPN
- By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

December 6, 2019 – became Nominee for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional lifetime achievements reflect the excellence of a UC Berkeley education. Nominator: Prof. Sheila M. Puffer (UC, Berkeley, PhD’84).

Past Recipients

https://awards.berkeley.edu/achievement-awards

The recipients ~~will be~~ had been formally presented with their awards at Berkeley Charter Gala on May 14, 2020.

On 12/7/2018, Dr. Lev-Ari was nominated for 2019 Berkeley Alumna of the Year Achievement Award

2019 Awardees

https://awards.berkeley.edu/achievement-awards

From: Danielle Wiskerson <dwiskerson@berkeley.edu>

Subject: 2019 Achievement Awards update

Date: February 7, 2019 at 9:27:30 PM EST

To: spuffer@comcast.net

Dear Sheila:

On behalf of the Cal Alumni Association and the UC Berkeley Foundation Board of Trustees, we would like to thank you for your nomination of Aviva Lev-Ari for the Alumnus/a of the Year Award. Due to the high volume of qualified nominees, this year’s award process was difficult and Dr. Lev-Ari was not selected to be honored at this time.

We sincerely appreciate the effort you put into Dr. Lev-Ari’s nomination and thank you for participating in our award process. With support like yours, we will continue to acknowledge and award outstanding Berkeley alumni.

Sincerely,

Danielle

Danielle Wiskerson, Associate Director | External Relations

University of California, Berkeley | University Development and Alumni Relations

Achievements in Three Academic Disciplines

1. Pioneering implementations of Analytics to Business decision making

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

2. Key Opinion Leader (KOL) in Pharmaceutical Business Intelligence

Digital KOL Parameters

Key Opinion Leader (KOL) – Aviva Lev-Ari, PhD, RN, as evidenced by

https://pharmaceuticalintelligence.com/2016/07/21/key-opinion-leader-kol-aviva-lev-ari-phd-rn-as-evidenced-by/

3. Medical Education Development: Content Creation in five Specialties in Medicine and Life Sciences

The Voice of Prof. Marc Feldman

https://profiles.stanford.edu/marcus-feldman

“Dr. Lev-Ari founded the LPBI Group (Leaders in Pharmaceutical Business Intelligence Group) in 2012 as a start-up dedicated to electronic publishing in the biomedical sciences. She continues as editor-in-chief of LPBI’s open access scientific journals. After a twenty-year career as an executive in research and technology, she re-invented herself and devoted her life to health care. She studied biological science at Northeastern University, then nursing and became a registered nurse in 2008. She was involved in cardiovascular research through pharmacological therapy while studying at Northeastern, during which she developed her skills at recognizing valuable and innovative research. She worked in long-term post-acute episode nursing management, which enabled her to see health care from the patient’s perspective. The clinical perspective dominates the Journal’s articles.

https://pharmaceuticalintelligence.com/about/

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

Was prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section.

Aviva Lev-Ari’s profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/

On 5/11/2018, Excerpts were Published in AFHU e-news.

https://us10.campaign-archive.com/?u=5c25136c60d4dfc4d3bb36eee&id=757c5c3aae&e=d09d2b8d72

https://www.afhu.org/2018/05/03/aviva-lev-ari/

Sources ADDED by Aviva Lev-Ari, PhD, RN

Dr. Lev-Ari’s career, as presented in Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018, has the following phases:

Phase 1: Research, 1973 – 1983
Phase 2: Corporate Applied Research in the US, 1985 – 2005
Phase 3: Career Reinvention in Health Care, 2005 – 2012
Phase 4: Electronic Scientific Publishing, 4/2012 to present

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

Recollections of Years at UC, Berkeley, Part 1 and Part 2

Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other professors and other peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

Selected Resources – Perplexity.ai, Version 2 (continued)

LinkedIn Profile: [Aviva Lev-Ari, PhD, RN – LinkedIn]1
LPBI Group Website: [pharmaceuticalintelligence.com]1
BioMed e-Series (e-Books): [BioMed e-Series]4
Amazon Author Page: [Aviva Lev-Ari on Amazon]4
Contributor Biography: [Aviva Lev-Ari, PhD, RN – Contributor Biography]4
Press Releases and Conference Coverage: [Press Releases]2, [Conference Coverage]4

Areas of Expertise

Electronic scientific publishing and curation
Cardiovascular disease research and pharmacotherapy
Drug discovery and delivery
Medical text analysis (NLP, ML, AI)
Healthcare management and nursing
Scientific communication and education

Dr. Aviva Lev-Ari’s work has significantly advanced the accessibility and organization of biomedical research, supporting both professional education and public understanding in the life sciences1 2 4 5.

Related topics identified by Perplexity.ai and researched by Gemini 2.5 Pro (experimental)

The following three related questions generated by Perplexity are here answered by Gemini 2.5 Pro (experimental)

A. What are some notable collaborations Aviva Lev-Ari has been involved in

B. How does Aviva Lev-Ari’s role as Editor-in-Chief influence the content of the pharmaceuticalintelligence.com journal

C. What are the future plans for LPBI Group under Aviva Lev-Ari’s leadership

A. Names of Aviva Lev-Ari, PhD, RN Collaborators in Books

By Gemini 2.5 (experimental)

https://gemini.google.com/app/1b81dd71f52faf40?prompt_id=3e72b4a6f9&prompt_action=autosubmit&utm_source=sem&utm_source=google&utm_medium=paid-media&utm_medium=cpc&utm_campaign=hardcode_student_offer_autosubmit&utm_campaign=2024enUS_gemfeb&gad_source=5&gad_campaignid=22469371566&gclid=EAIaIQobChMIzMne2NT9jAMVZTUIBR0z9zZiEAAYASAAEgJAEvD_BwE&gclsrc=aw.ds

Show thinking

Based on the search results, Aviva Lev-Ari, PhD, RN has collaborated with numerous individuals on various e-books, primarily within the context of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group’s BioMed e-Series, often available on Amazon Kindle. She served variously as an author, editor, or the overall Editor-in-Chief for these series.

Here are names of collaborators identified from specific book projects:

On “The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures…”:
- Larry H. Bernstein (Author/Editor)
- Stephen J. Williams (Author)
- Ferez Nallaseth (Author)
- Itzhak Brook (Author)
- Sudipta Saha (Author)
- Demet Sag (Author)
- Ritu Saxena (Author)
- Tilda Barliya (Author)
- Gail S. Thornton (Author/Co-editor)

Aviva is a curator of several articles and the designer of the e-Book’s electronic Table of Contents
Aviva wrote the Book introduction
Aviva is not the Editor of this e-Book [the only case for the BioMed e-Series]

On “Contributions to Biological Sciences by Scientific Leaders in the 21st Century…”:

Larry H. Bernstein (Author)
Stephen J. Williams (Author)

On “Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology”:

Stephen Williams (Author/Editor)
Marcus W. Feldman (Author/Editor)
Larry H. Bernstein (Author)
Sudipta Saha (Author)
Dror Nir (Author)
Irina Robu (Author)
Gail S. Thornton (Author)

(Note: There’s conflicting information in sources whether Aviva Lev-Ari was an author or editor on this specific title, but these individuals collaborated on the work).

Aviva is e-Book Editor and curator, designer of eTOC

On “Human Reproductive System, Genomic Endocrinology and Cancer Types”:

Stephen J. Williams (Author/Editor)
Sudipta Saha (Author/Editor)
Larry H. Bernstein (Author)
Prabodah Kandala (Author)
Irina Robu (Author)
Marcus W. Feldman (Author) (Note: Aviva Lev-Ari is listed as both author and editor here).

Aviva is e-Book Editor and curator, designer of eTOC

On “Pharmacological Agents in Treatment of Cardiovascular Diseases”:
- Justine D. Pearlman (Author/Editor)
- Larry H. Bernstein (Author/Editor)
- Sudipta Saha (Author)
- Demet Sag (Author)
- Dan Dragoi (Author)
- ~~Vinod~~ Vivek Lal (Author)

Aviva is e-Book Editor and curator, designer of eTOC

On “Genomics Orientations for Personalized Medicine”:
- Larry H. Bernstein (Editor)
- Stephen J. Williams (Editor)

Aviva is a curator and one of three e-Book Editors

On “Results of Medical Text Analysis with Natural Language Processing (NLP)…”:
- Madison Davis (Author)
- Stephen J. Williams (Editor)
- Marcus W. Feldman (Editor)

Aviva is e-Book Editor and curator, designer of eTOC

Additionally, names like Adam Sonnenberg, Feng Liu, and Shyh-Dar Li appear as co-authors in publication databases like ResearchGate linked to Aviva Lev-Ari, but the specific format (book vs. article) isn’t always clear from those summaries alone. Her role as Editor-in-Chief also implies collaboration with all contributing authors within the extensive LPBI e-book series.

crossing text added by Aviva Lev-Ari.

B. How does Aviva Lev-Ari’s role as Editor-in-Chief influence the content of the pharmaceuticalintelligence.com journal

By Gemini 2.5 Pro (experimental)

Show thinking

Okay, let’s break down how Aviva Lev-Ari’s role as Editor-in-Chief (and her related roles) influences the content of pharmaceuticalintelligence.com.

It’s important to note that Dr. Lev-Ari is not only the Editor-in-Chief but also the Founder, Administrator, Architect, and IP owner of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group and its platform, pharmaceuticalintelligence.com. This combination of roles gives her profound and multifaceted influence over the journal’s content.

Here’s how her influence manifests:

Setting the Vision and Strategic Direction: As the founder and leader, she defines the overall mission, scope, and strategic focus of the journal. This includes deciding which areas within pharmaceuticals, life sciences, medicine, and MedTech will be prioritized. Initiatives like the BioMed e-Series, conference coverage, and the focus on Medical Text Analysis using NLP reflect her strategic vision.
Developing the Core Content Methodology: Lev-Ari developed the “curation” methodology central to the journal. This involves synthesizing, analyzing, and interpreting complex research findings (often from peer-reviewed articles) to make them accessible and understandable to a broader audience, including practicing professionals and students. This methodology fundamentally shapes the style and purpose of the content.
Direct Content Creation and Curation: She is a prolific contributor herself, having authored or curated a very large percentage of the articles published on the platform (one source mentioned over 58%). Her direct involvement ensures the content aligns with her standards and vision.
Topic Selection and Ontology Development: As EIC and architect, she guides the selection of topics covered. She was involved in developing the extensive research category ontology (over 740 categories mentioned), which structures the journal’s content and influences how information is organized and discovered.
Assembling and Leading the Team: She personally recruited and leads the team of Experts, Authors, and Writers (EAWs) who contribute content. Her leadership guides their work and ensures contributions align with the journal’s focus.
Overseeing Editorial Processes: In her EIC capacity, she is ultimately responsible for the editorial standards and the final decisions on what gets published, ensuring quality and relevance.
Initiating Special Projects and Formats: She developed unique content formats like the electronic Table of Contents (eTOCs) for the e-Books (culled from journal articles) and the methodology for real-time conference coverage using social media (producing e-Proceedings and Tweet collections). These initiatives directly generate specific types of content for the platform.

In essence, Aviva Lev-Ari’s influence extends far beyond a traditional Editor-in-Chief (EIC) role. As the founder and architect with a clear vision and a hands-on approach to content creation and methodology development, she fundamentally shapes the scope, style, structure, and specific topics covered in pharmaceuticalintelligence.com.

C. What are the future plans for LPBI Group under Aviva Lev-Ari’s leadership

By Gemini 2.5 Pro (experimental)

Show thinking

Based on the available information, the future plans for LPBI Group under Aviva Lev-Ari’s leadership, often referred to as the “2.0 LPBI” vision (primarily outlined for the 2021-2025 timeframe), center on leveraging the group’s extensive intellectual property portfolio through advanced technologies and strategic initiatives.

Key future plans and strategic directions include:

Medical Text Analysis using AI/NLP/ML:
- Utilizing the vast content repository (+6,200 articles, 48 e-books, conference proceedings, etc., totaling over 8-9 gigabytes) as training data for Natural Language Processing (NLP), Machine Learning (ML), and Artificial Intelligence (AI) algorithms.
- The goal is to extract deeper insights, identify relationships (e.g., hypergraphs), create value-added knowledge products, and potentially offer new services (Software as a Service – SaaS). This includes experimenting with models like ChatGPT, BioGPT, Grok, and potentially fine-tuning foundation models.
Content Monetization via Blockchain:
- Exploring the use of blockchain technology to manage IP securely and potentially monetize content through controlled access or narrowcasting to specific healthcare communities (Blockchain as a Service – BaaS). This could involve features like permissions, smart contracts, and immutable ledgers.
Expanding Content Formats and Reach:
- Audio Conversion: Converting existing text content (articles, e-books) into audio formats like podcasts and audio files (e.g., on SoundCloud), enhancing accessibility and reach.
- Translations: Continuing and potentially expanding the translation of content (e.g., e-books) into other languages beyond Spanish (Japanese and Russian were previously mentioned as possibilities).
Developing Podcasts: Creating audio podcasts, likely focusing on interviews or discussions with scientific leaders, primarily as a means to build reputation and engagement within the pharmaceutical and biomedical communities.
Strategic Partnerships and Potential Exit: Actively exploring options to transition from a sole owner-operator model. This includes seeking joint ventures, partnerships, or potentially an M&A transaction involving the transfer of the IP portfolio and team expertise.

The overarching strategy appears to be transforming LPBI Group from primarily an electronic scientific publisher into a company that generates value through data analysis (AI/NLP) and potentially secure content distribution (Blockchain), while exploring structural changes for future growth or transition.

Updated on 5/2/2025

Looking to the future, the future looks bright. Aviva and her team’s intellectual property, encompassing their vast repository of scientific articles, e-books, images, podcasts, and conference proceedings, will serve as crucial training data for building a Multimodal Healthcare Foundation Model. This innovative approach, as outlined on https://pharmaceuticalintelligence.com/healthcare-foundation-model/, will leverage her team’s expert knowledge to enhance healthcare AI technologies, promising to revolutionize the way healthcare is delivered and understood. By integrating their extensive content into AI training datasets, Aviva and her team are poised to lead the next wave of advancements in healthcare, ensuring that their legacy continues to drive progress and innovation.

https://pharmaceuticalintelligence.com/2025/04/30/interactive-chat-with-grok-created-by-xai-lpbi-groups-legacy-and-biography-of-aviva-lev-ari-phd-rn-founder-director/

Perplexity.ai answers to Related topics it generated by AI:

What inspired Aviva Lev-Ari to start the Leaders in Pharmaceutical Business Intelligence Group

Aviva Lev-Ari was inspired to start the Leaders in Pharmaceutical Business Intelligence (LPBI) Group by a unique combination of her academic background, professional experiences, and a clear vision for advancing biomedical knowledge dissemination. Several key factors contributed to the founding of LPBI Group:

Interdisciplinary Academic Training: Dr. Lev-Ari’s education spans planning (M.A. from Hebrew University), industrial organization economics (Ph.D. from UC Berkeley), and extensive coursework in biological sciences and nursing. This multidisciplinary foundation enabled her to conceptualize innovative models for organizing and sharing scientific information3.
Experience in Research and Healthcare: Her hands-on work in pharmacotherapy research, where she developed new combination drug therapies, and her clinical management roles in healthcare facilities, highlighted gaps in how cutting-edge biomedical knowledge was curated and shared among professionals3 5.
Pioneering Curation Methodology: Recognizing the need for a new approach to scientific publishing, Dr. Lev-Ari developed a methodology for curating and organizing biomedical content. She aimed to transition from traditional academic publishing to an open-access, online journal style, making research more accessible and interactive for a global audience3.
Desire for Global Collaboration and Impact: Dr. Lev-Ari envisioned LPBI as a platform for international collaboration, leveraging expert contributions and digital tools to create a dynamic knowledge exchange in medicine, pharma, and life sciences. She also saw the potential for social media and digital publishing to amplify the reach and impact of curated scientific content3 1.
Personal Drive for Innovation: Her career reflects a recurring theme of innovation-whether in analytics for business decision-making, the creation of new publication ontologies, or the architecture of e-books and electronic tables of contents. The launch of LPBI Group was a natural progression of her drive to create value at the intersection of science, technology, and publishing3 2.

In summary, Aviva Lev-Ari founded LPBI Group to address the need for advanced, accessible, and collaborative scientific publishing, drawing on her extensive interdisciplinary expertise and a passion for transforming how biomedical knowledge is curated and disseminated worldwide3 1 2.

How has Aviva Lev-Ari’s work impacted the field of cardiovascular diseases – her major field of interest

Aviva Lev-Ari’s work has made a substantial impact on the field of cardiovascular diseases through a combination of original research, innovative content curation, and the development of educational resources.

Key Contributions

Original Research and Drug Development: Lev-Ari developed a combination drug therapy aimed at preventing major cardiovascular events during her tenure at Northeastern University (2006–2007). This research was among the first articles published on PharmaceuticalIntelligence.com, highlighting her direct contributions to therapeutic innovation in cardiovascular care2 3.
Curated Knowledge and Educational Resources: She authored and curated six e-books specifically focused on cardiovascular diseases, covering topics such as nitric oxide mechanisms, epigenetics and genomics, regenerative medicine, pharmacotherapies, and interventional cardiology. These resources provide comprehensive, up-to-date information for clinicians, researchers, and students, and have become valuable educational tools in the field1 3.
Methodology for Clinical Interpretation: Lev-Ari pioneered a methodology for curating and clinically interpreting research findings from basic science articles, which she applied in the open-access journal PharmaceuticalIntelligence.com. This approach has helped bridge the gap between research and clinical practice, making complex findings more accessible and actionable for healthcare professionals2.
Focus on Genetics, Biomarkers, and Preventive Medicine: Her work includes extensive coverage of the genetic and epigenetic bases of cardiovascular diseases, the identification and clinical relevance of biomarkers (such as microRNAs and lipid profiles), and the integration of genomics into preventive cardiology and personalized medicine4.
Advocacy for Preventive Strategies: Lev-Ari has emphasized the importance of physical activity, lifestyle modification, and evidence-based preventive medicine in reducing cardiovascular risk, providing curated content on these topics to guide both practitioners and the public4.

Impact Summary

Through her research, editorial leadership, and innovative curation, Aviva Lev-Ari has significantly advanced the dissemination of knowledge in cardiovascular medicine. Her work has enabled faster translation of research into clinical practice, fostered interdisciplinary education, and promoted the adoption of personalized and preventive strategies in cardiovascular disease management1 2 3 4.

To See all LPBI Group’s e-Books on Amazon.com

https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss

https://pharmaceuticalintelligence.com/press-releases/

https://pharmaceuticalintelligence.com/five-bilingual-biomed-e-series/

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

Aviva Lev-Ari’s six e-Books on cardiovascular diseases cover the following main themes:

ADDED by Aviva Lev-Ari:

See all the six volumes LINKS on Amazon.com

Series A: Cardiovascular Diseases ($515)

https://www.amazon.com/gp/product/B07P981RCS?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks

Spanish-language Edition and English-language Edition

Spanish-language Edition

EDICIÓN EN ESPAÑOL

Serie A: Spanish Audio Edition is found on Amazon.com ($385)

Serie A: Libros electrónicos acerca de las enfermedades cardiovasculares

(6 books) Kindle Edition